WILLIAM G. BORNMANN, Ph.D. 3523 Oyster Cove Drive • Missouri City, Texas 77459-3028 (Cell) 281-415-2703 • (Home) 281-969-5303 • [email protected] Skype: William.bornmann1

Former Chair, Greater Houston Section of the American Chemical Society

EDUCATION

Ph.D. Organic Chemistry 1988 University of Vermont Burlington, Vermont

Dissertation: Part I: The of (±)-Catharanthine and (±)-Tabersonine; Part II: The Total Synthesis of 20'-Desethyl-20'-Deoxy Vinblastine and 20'-Desethyl-20'-Deoxy-Vincovaline.

M.S. Synthetic Organic Chemistry 1978 Montana State University Bozeman, Montana

Dissertation: New Synthetic Methodologies for Natural Products.

B.S. Chemistry and Biology 1975 University of Wisconsin River Falls, Wisconsin

PROFESSIONAL EXPERIENCE

Houston Community College Houston, Texas I have taught the following courses: Chem 2423 (Organic Chemistry I) Fall 2015 / Spring 2016 / Summer 2016 / Fall 2017 Chem 2425 (Organic Chemistry II) Fall 2016 / Fall 2017 / Summer 2017 Chem 1311 (General Chemistry I) Fall 2016 / Spring 2017/ Spring 2018 / Fall 2018/Fall 2019/Spring 2020 Chem 1312 (General Chemistry II) Summer 2018 Chem 1305 (Introduction to Chemistry) Spring 2016/Fall 2019/Spring 2020

2

Willowcroft Health, Inc. Denver, Colorado

CTO 2019 – Present In August of 2019, I became the CTO of Willowcroft Health with the primary focus on the design and development of new proprietary chemotherapeutic agents for the treatment of cancer.

Gulf Coast Institute for Drug Discovery Houston, Texas

President, CEO and Founder 2019 – Present In August of 2019, I formed Gulf Coast Institute for Drug Discovery with the primary focus on the design and development of new proprietary chemotherapeutic agents.

UNIVERSITY OF TEXAS-MD ANDERSON CANCER CENTER Houston, Texas

Professor, Director, Translational Chemistry Core Facility 2008 – 2014 Division of Cancer Medicine In 2008 I was made the Director of the newly created Translational Chemistry Core Facility at University of Texas – MD Anderson Cancer Center as Professor. My primary responsibility was the design and development of new proprietary chemotherapeutic agents for the treatment of cancer. In this position, I provided technical expertise and advice to investigators throughout the institution on a daily basis concerning their therapeutic needs. In addition to the managing the day to day operations of the laboratory, I also managed issues with administrators as well as patent attorneys. In association with these duties I also directed and mentored five research scientists.

Co-Director, Center for Biomolecular Structure and Function 2007 - 2014 University of Texas - M.D. Anderson Cancer Center

Professor, Head, 2003 – 2008 Chemistry Section of the Department of Experimental Diagnostic Imaging Division of Diagnostic Imaging In 2003 I was recruited to the University of Texas – MD Anderson Cancer Center as Professor and Head of the Chemistry Section in the newly created Department of Experimental Diagnostic Imaging. My primary responsibility was the design and development of new imaging agents for the diagnosis of cancer based on signal transduction pathways. These new imaging agents were to be a critical focal point for the Institute's clinical and basic research activities. In addition, I was to design and develop new chemotherapeutic agents and to provide technical expertise and advice to investigators throughout the institution on a daily basis. In addition to the managing the day to day operations of the laboratory, I also managed issues with administrators as well as patent attorneys. In association with duties, I also directed and mentored eight postdoctoral fellows and two laboratory technicians.

MEMORIAL SLOAN-KETTERING CANCER CENTER New York, New York

Laboratory Member, Head, Core Facility 1993 - 2003

In 1993, I was promoted to Laboratory Member and Head of the Organic Syntheis Core Facility at Memorial Sloan-Kettering Cancer Center. My primary responsibility was to spearhead the design and development of new chemotherapeutic agents for the treatment of cancer as well as and the total synthesis of natural products and analogues critical for the Institute's clinical and basic research activities. I 3 provided technical expertise and advice to investigators throughout the institution. In addition to the managing the day to day operations of the laboratory, I also managed issues with administrators as well as patent attorneys. In addition to these duties I also directed and mentored the development of four postdoctoral fellows as well as directed and three laboratory technicians.

Associate Laboratory Member 1991-1993 Manager of the Laboratory for Bio-Organic Chemistry

I was the laboratory manager for Professor Samuel Danishefsky in the Laboratory of Bio-Organic Chemistry at Memorial Sloan-Kettering Cancer Center. My primary responsibilities was the design and synthesis of new based anti-cancer chemotherapeutic agents, and to interact with scientists throughout the institution and help them with their therapeutic needs. In addition, I directed every facet of the daily laboratory operations and mentored / guided the research work of seven postdoctoral fellows. Our work resulted in many high-profile publications. In addition, I was also responsible for the positive working relationships with administrators and patent attorneys.

ACADEMIC AFFILIATIONS

Professor of Experimental Therapeutics 2009 - 2014 University of Texas - M.D. Anderson Cancer Center Houston, Texas Taught Graduate level course GS04-1103 Principles of Therapeutics

Adjunct Professor of Pharmacology 2010 – Present Baylor College of Medicine Houston, Texas Taught Graduate level course GS-PG-426 General Pharmacology

Adjunct Professor of Bioengineering 2006 – 2012 Rice University Houston, Texas Lectured in BIOE 515- Systems Biology and Molecular Design

Adjunct Professor of Chemistry 2001 – 2003 New York University New York, New York Taught the following Graduate level courses: • G25.1311 Organic Reactions • G25.1312 Strategies in Organic Synthesis • G25.2232 Total Synthesis of Natural Products

RECENT PUBLICATIONS BOOKS:

Fernandes, C.L., S.J. Chavan, J.H. Dong, W.G. Bornmann, B. Polsky, F.V. Chisari, J.A. Montali, D.E. Schmidt, and H.J. Prochaska. "Regulation of gluththione S-transferases: Clues from a worm, a virus and a mouse with hepatitis." International ISSX-Workshop on Glutathione S- transferasees Noordwijerhout The Netherlands, Apr. 22-25, 1995.

JOURNALS:

1. Mundy BP, Bornmann WG. A novel entry into 3-acetyl cyclohexanone via a Cope rearrangement. Tetrahedron Lett (1978), (11), 957-960.

4 2. Mundy BP, Bornmann WG. The apparatus and procedure for Cope rearrangement of the pyrrolidino enamine of 2-acetyl-6-methyl-3,4-dehydro (2H) pyran. Synthetic Communications (1978), 8(4), 227-230.

3. Mundy BP, Bornmann WG, Lipkowitz KB, Scarpone S. Formation and synthetic utility of dihydro- and dihtdrothiapyrans. J Org Chem (1979), 44(4), 486-493.

4. Mundy BP, Bornmann WG. A simple synthesis of the multipurpose pheromone of Mus musculus. J Org Chem (1984), 49(26), 5264-5265.

5. Kuehne ME, Bohnert JC, Bornmann WG, Kirkemo CL, Kuehne SE, Seaton PJ, Zebovitz TC. Biomimetic synthesis of indole . 11. Synthesis of ß-Carboline and Indoloazepine Intermediates. J Org Chem (1985), 50(7), 919-924.

6. Kuehne ME, Bornmann WG, Early WG, Marko I. Studies in biomimetic syntheses. 14. Controlled, selective synthesis of Catharanthine and Tabersonine and related desethyl compounds, through generation of 15-oxosecodine intermediates. J Org Chem (1986), 51(15), 2913-2927.

7. Kuehne ME, Podhorez DE, Mulamba T, Bornmann WG. Biomimetic alkaloid synthesis. 15. Enantioselective synthesis with epichlorohydrin: Total Synthesis of (+), (-) and racemic Vindoline and a synthesis of Vindorosine. J Org Chem (1987), 52(3), 347-353.

8. Kuehne ME, Zebovitz TC, Bornmann WG, Marko I. Three routes to the critical C16'-C14' PARF relative stereochemistry of Vinblastine. Synthesis of 20'-Desethyl 20'- Deoxyvinblastine and of 20'-Desethyl 20'-Deoxyvincovaline. J Org Chem (1987), 52(19), 4340-4349.

9. Kuehne ME, Bornmann WG. Syntheses of 20'-deoxyvinblastine, 20'-Deoxyleurosidine, 20'- Deoxyvincovaline, 20'-epi-20'-Deoxyvincovaline, and 20'-Deoxyvincristine and its 20'- epimer through racemic and enantioselectively generated intermediates. New syntheses of D/E-cis- and trans-pseudo -Vincadifformines and D/E-cis-and trans-20-epi- pseudo - Vincadifformines.J Org Chem (1989), 54(14), 3407-3420.

10. Kuehne ME, Bornmann WG, Parsons WH, Spitzer TD, Blount JF, Zubieta J. Total syntheses of (±)-Cephalotaxine and (±)-Oxocephalotaxine. J Org Chem (1988), 53(15), 3439-3450.

11. Spitzer T, Kuehne ME, Bornmann WG, Anklin C. The effect of spin-lock pulses on two- spin coherences: An application to proton-detected Heteronuclear Correlation. J Magn Reson (1989), 84(3), 654-657.

12. Kuehne ME, Matson PA, Bornmann WG. Enantioselective syntheses of Vinblastine, Leurosidine, Vincovaline and 20'-epi-Vincovaline. J Org Chem (1991), 56(2), 513-528.

13. Beecher DC, Teitler M, Suderlund DM, Bornmann WG, Kuehne ME, Glick SD. Mechanisms of action of Ibogaine and Harmaline Congeners based on radiologic and binding studies. Brain Research (1992), 571(2), 242-247.

5 14. Bornmann WG, Kuehne ME. A common intermediate providing syntheses of - Tabersonine, Coronaridine, Iboxyphylline, Ibophyllidine, Vinamidine, and Vinblastine. J Org Chem (1992), 57(6), 1752-1760.

15. Borman LS, Bornmann WG, Kuehne ME. Modulation of drug cytotoxicity in wild type and multidrug-resistant tumor cells by stereoisomeric seris of C-20'- Vinblastine Congeners that lack antimicrotubule activity. Cancer Chemother. and Pharmacol. (1993), 31(5), 343- 349.

16. Queneau Y, Krol WJ, Bornmann, WG, Danishefsky SJ. Nozaki-Kishi reaction of crotonates as a source of complex dienophiles: Application to the B-seco Taxane series. Bull Soc Chim Fr. (1993), 130(3), 358-370.

17. Shen W, Coburn CA, Bornmann WG, Danishefsky SJ. Concise total synthesis of dl- Camptothecin and related anticancer drugs. J Org Chem.(1993), 58(3), 611-617.

18. Queneau Y, Krol WJ, Bornmann WG, Danishefsky SJ. A ready synthesis of intermediates containing the A-ring substructure of taxol: A Diels-Alder route to the B-seco taxane series. J Org Chem (1992), 57(14), 4043-4047.

19. Magee TV, Bornmann WG, Isaacs RC, Danishefsky SJ. A straightforward route to functionalized intermediates containing the CD substructure of Taxol. J Org Chem (1992), 57(12), 3274-3276.

20. Masters JJ, Jung DK, Bornmann WG, Danishefsky SJ. A concise synthesis of a highly functionalized C-aryl taxol analog by an intramolecular Heck olefination reaction.Tetrahedron Lett. (1993), 34(45), 7253-7256.

21. Snyder L, Shen W, Bornmann WG, Danishefsky SJ. Synthesis of 18- Noranhydrocamptothecin Analogs Which Retain topoisomerase I Inhibitory Function . J Org Chem (1994), 59(23), 7033-7037.

22. Joseph CK, Wright SD, Bornmann WG, Randolph JT, Kumar ER, Bittman R, Liu J, Kolesnick RN Bacterial Lipopolysaccharide has Structural Sililarity to Ceramide and Stimulates Ceramide-activated Protein Kinase in Myeloid Cells J Biol. Chem. (1994), 269(26), 17606-17610.

23. Bornmann WG, Roepe PD Analysis of Drug Transport Kinetics in Multidrug Resistant Cells Using a Novel Coumarin-Vinblastine Compound Biochemistry 1994), 33(4), 12665- 12675.

24. Prochaska HJ, Bornmann WG, Barron P, Polsky B.Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by 7-methyl-6,8- bis(methylthio)pyrrolo-[1,2-a]-pyrazine, an in vivo metabolite of oltipraz Mol. Pharmacol. (1995), 48(1), 15-20.

25. Prochaska HJ, Bornmann WG, Chavan, S.J., Flexner C.Inactivation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase by Oltipraz: Evidence for the formation of a Stable Adduct, Arch. Biochem. Biophys.(1995), 324(1), 143-152.

6 26. Dong JG, Bornmann W, Nakanishi K, Berova N, Structural Studies of Vinblastine Alkaloids by Exciton Coupled Circular Dichroism Phytochemistry (1995), 40(6), 1821- 1824.

27. Danishefsky SJ, Masters JJ., Young WB., Link, JT., Snyder LB, Magee TV, Jung DK, Issacs RCA, Bornmann WG, Alaimo CA, Coburn CA, Di Grandi MJ. Total Synthesis of Baccatin III and Taxol J. Amer. Chem. Soc. (1996), 118 (12), 2843-2859.

28. Kothari P.J., Finn R.D., Bornmann W.G., Agus D.B., Vera J.C., Larson S.M. Chemical Consequences Resulting from Multi-millicurie Preparation of 6-[18F]-6- deoxy-L-ascorbic Acid Radiochimica Acta (1997), 77(1-2), 87-90.

29. Sin, N., Meno, L., Wang M.o.W., Men J.J., Bornmann W.G., Crews C.M.,(1997) The anti- angiogenic agent fumagillin covalentyl binds and inhibits the methionine aminopeptidase, MetAP-2 Proc. Nat. Acad. Sci. USA (1997), 94(12), 6099-6103

30. Wuerzberger, S.M., Pink, J. J., Planchon, S. M., Byers K.L. Bornmann, W. G. Boothman, D. A.., Induction of Apoptosis in MCF-7:WS8 Breast Cancer Cells by beta-Lapachone Cancer Research, (1998), 58(9), 1876-1885.

31. Aschele, C., Baldo, C., Sobrero, A. F., Debernardis, D., Bornmann, W.G., Bertino, J. R., Schedule-dependent Syngergism between Raltitrexed and Irinotecan in Human Colon Cancer Cells in Vitro Clinical Cancer Research (1998), 4(5), 1323-1330.

32. Chou T.C., Depew K.M., Zheng, Y.H., Safer M.L., Chan D., Helfrich B., Zatorska, D., Zatorski, A., Bornmann W., Danishefsky S.J., Reversal of Anticancer Multidrug Resistance by the Ardeemins Proc. Nat. Acad. Sci. USA (1998), 95(14), 8369-8374.

33. Byrd C.A., Bornmann w., Erdjument-Bromage H., Tempst P., Pavletich N., Rosen N., Nathan C.F., Ding A., Heat Shock Protein 90 mediates macrophage activation by taxol and bacterial lipopolysaccharide Proc. Nat. Acad. Sci. USA(1999), 96(10), 5645-5650.

34. Parish C., Dong J.G., Bornmann W., Chang, J., Nakanishi K., Berova N., Circular Dichroism studied of bisindole Vinca alkaloids Tetrahedron (1998), 54(52), 15739-15758.

35. Ragupathi G., Slovin S., Adluri S., Sames D., Kim I. J., Kim H. M., Spassova M., Bornmann Wm. G., Lloyd K. O., Scher H. I., Livingston P. O., Danishefsky S. J., A Fully Synthetic globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle Angew. Chem. Int. Ed. (1999), 38(4), 563-566.

36. Slovin S., Ragupathi G., Adluri S., Ungers G., Terry K., Spassova M., Bornmann Wm. G., Fazzari M., Dantis L., Olkiewicz K., Lloyd K. O., Livingston P. O., Danishefsky S. J., Scher H. I., Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic golbo H hexasaccharide conjugate in man Proc. Nat. Acad. Sci. USA. (1999), 96(10), 57105715.

37. Planchon, S. M., Wuerzberger-Davis, S.M., Pink, J. J., Robertson K.A., Bornmann, W. G. Boothman, D. A., Bcl-2 protects against -Lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells Oncology Reports (1999), 6(3),485- 492.

7 38. Depew K.M., Marsden S.T., Zatorska, D., Zatorski, A., Bornmann W., Danishefsky S.J., Total Synthesis of 5-N-Acetylardeemin and Amouromine J. Amer. Chem. Soc. (1999), 121(51), 11953-11963.

39. Schindler T., Bornmann W., Pellicena P, Miller W.T., Clarkson B., Kuriyan J., Structural Mechanism for STI-571 Inhibition of Abelson tyrosine kinase, Science (2000), 289 (5486) 1938-1942.

40. Sabbatini P., Kudryashov V., Danishefsky S, Livingston P.O., Ragupathi G., Bornmann W.G., Spassova M., Zatorski A., Spriggs D., Aghajanian C., Soignet S., Peyton M., O’Flaherty C., Curtin J., Lloyd K.O., Immunization of Ovarian Cancer Patients with a Synthetic Lewis y-protein Conjugate Vaccine: Clinical and Serological Results International Journal of Cancer (2000), 87(1), 79-85.

41. Sanchez-Carbayo MS, Bornmann W., Cordon-Cardo C., DNA microchips:Techinical and Practical Considerations, Curr Org Chem (2000), 4(9) 945971.

42. Wang, Z.G., Williams, L.J., Zhang X.F., Zatorski A., Kudryashov V., Ragupathi G., Spassova M., Bornmann W.G., Slovin S.F., Scher H.I., Livingston P.O., Lloyd K.O., Danishefsky S, Polyclonal Antibodies from Patients Immunized with a globo H-keyhole limpet hemocyanin vaccine: Isolation, Quantification and Characterization of Immune Response Using Totally Synthetic Immobilized Tumor Antigens Proc. Nat. Acad. Sci. USA. (2000), 97(6), 2719-2724.

43. Li, X., Motwani M., Tong W., Bornmann W., Schwartz G.K., Huanglian, a Chinese herbal extract, inhibits cell growth by suppressing the expression of Cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol. Pharmacol. (2000) 58(6), 12871293.

44. Liang, X., Nazarian, A., Erjument-Bromage, H., Bornmann, W., Tempst, P., and Resh, M.D. (2001) Heterogeneous fatty acylation of Src family kinases with polyunsaturated fatty acids regulates raft localization and signal transduction. J Biol. Chem. (2001), 276(33), 30987- 30994.

45. Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, Finn R, Akhurst T, Larson S, Blasberg R, Sadelain M, Tjuvajev JG. Imaging TCR-dependent NFAT- mediated T-cell activation with positron emission tomography in vivo. Neoplasia.( 2001), 3(6), 480-488.

46. Sirotnak, F.; Wendel H.G.; Bornmann W.G.; Tong, W.P.; Miller, V.A.; Scher, H.I.; Kris, M.G. Co-Admistration of probenceid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo Clinical Cancer Research (2000), 6(9), 3705-3712.

47. Stachel, S.J.; Lee, C.B.; Spassova, M.; Chappell, M.D.; Bornmann Wm.G.; Danishefsky, S.J.; Chou T-C; Guan, Y.; On the interactivity of complex synthesis and tumor pharmacology in the drug discovery process: total synthesis and comparative in vivo evaluations of the 15- aza epothilones. J. Org. Chem. (2001), 66(12), 4369-4378.

48. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bornmann WG, Spassova M, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, 8 Livingston PO, Danishefsky SJ. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A.( 2001), 98(6), 3270-3275.

49. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R, Gelovani Tjuvajev J.Imaging transcriptional regulation of p53- dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A. (2001), 98(16), 9300-9305.

50. Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA. beta- Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.Exp Cell Res.( 2001), 267(1), 95-106.

51. Hofmann, R. M., Cotton, G. J., Bornman, W, Chang, E, Muir, Tom W. Fluorescent biosensor for CrkII phosphorylation by the Abl tyrosine kinase, Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001 (2001), 992-993.

52. Miyamoto S, Huang TT, Wuerzberger-Davis S, Bornmann WG, Pink JJ, Tagliarino C, Kinsella TJ, Boothman DA. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann N Y Acad Sci. (2000), 922, 274-92.

53. Ragupathi G., Cappello S., Yi S.S., Spassova M., Bornmann W.G., Danishefsky S. and Livingston P.O., Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines Vaccine (2002), 20(7-8), 1030-1038.

54. Swendeman S., Lambek C., Liu C., Wisniewski D., Strife A., Bornmann W.G., Veach D., Vidal E., Schindler T., Nagar B., Kuriyan J and Clarkson B.D., Characterization of potent inhibitors of the BCR-Abl and the c-kit receptor tyrosine kinases Cancer Research (2002), 62(15), 4244-4255.

55. Nagar B., Bornmann W.,Veach D., Pellicena P, Miller W.T., Clarkson B., Kuriyan J., Crystal Structure of the c-Abl Tyrosine Kinase Domain in Complex with PD173955 and STI- 571 Cancer Research (2002), 62(15), 4236-4243.

56. Hofmann R.M., Cotton G.J., Bornmann W.G., Chang E and Muir T.W. Fluorescent monitoring of kinase Activity in real time: developlent of a robust fluorescence-based assay for Abl tyrosine kinase activity Bio-Organic and Medicinal Chemistry Letters (2001), 11(24), 3091-3094.

57. Hackman, T., Dubrovin, M., Balatoni, J., Beresten, T., Ponomarev, V., Beattie, B., Finn, R., Bornmann, W., Blasberg, R.G., and Gelovani Tjuvajev, J. Monitoring E.coli cytosine deaminase gene expression by noninvasive imaging of the HSV-1-tk marker gene: Potential clinical applications in cancer gene therapy. Molecular Imaging, (2002), 1(1), 36-42.

58. Mayer-Kuckuk, P., Banerjee, D., Malhotra, S., Doubrovin, M., Iwamoto, M., Akhurst, T., Balatoni, J., Bornmann, W., Finn, R., Larson, S., Fong, Y., Gelovani Tjuvajev, J., Blasberg, R., and Bertino, R. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proc. Natl. Acad. Sci. USA, (2002), 99(6), 3400-3405. 9

59. J. Gelovani Tjuvajev, M. Doubrovin, T. Akhurst, S. Cai, J. Balatoni, M.M. Alauddin, R. Finn, W. Bornmann, B. Beattie, S. Larson, P. Conti, R. Blasberg. Comparison of Radiolabeled Nucleoside Probes (FIAU, FHBG and FHPG) for PET Imaging of HSV1-tk Gene Expression. J. Nucl. Med. 2002:43: 1072-1083.

60. Eva Marie Y. Moresco, Alfred J. Scheetz, William G. Bornmann, Anthony J. Koleske, and Reiko M. Fitzsimonds Abl family nonreceptor tyrosine kinases are required for normal short- term synaptic plasticity. J. Neuropysiology (2003), 89(3), 1678-1687.

61. G. Koehe, M. Doubrovin, E. Doubrovina, P. Zanzonico, H.F.Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldsein, G. Heller, C. May, V. Ponomarev, R. Finn, R. G. Blasberg, Wm. Bornmann, I. Riviere, M. Sadelain, R.. J. O’Reilly, S.M. Larson and J.G. Gelovani TjuvajevSerial In Vivo Imaging of the targeted Migration and Persistence of HSV-TK Transduced Human Antigen-Specific Lymphocytes Nature Biotechnology (2003), 21(14), 405-413.

62. B. Nagar, O. Hantschel, M. Young, K. Scheffzek, D. Veach, Wm Bornmann, B. Clarkson, G. Superti-Furga and J. Kuriyan, Structural basis for the auto-inhibition of c-Abl tyrosine kinase Cell (2003), 112(6), 859-871.

63. Spees WM, Yang G, Veach D, Rubio MB, Koutcher JA, Bornmann W. A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra. Mol Cancer Ther. (2003), 2(10): 933-9.

64. Nasongkla N, Wiedmann AF, Bruening A, Beman M, Ray D, Bornmann WG, Boothman DA, Gao J.Enhancement of Solubility and Bioavailability of -Lapachone using Cyclodextrin Inclusion Complexes Pharm Res. (2003), 20(10), 1626-33.

65. Tanis, K.Q., D. Veach, W.G. Bornmann, and A. Koleske. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation Mol Cell Biol. (2003), 23(11), 3884-96.

66. Kuehne ME, Bornmann WG, Marko I, Qin Y, LeBoulluec KL, Frasier DA, Xu F, Mulamba T, Ensinger CL, Borman LS, Huot AE, Exon C, Bizzarro FT, Cheung JB, Bane SL. Syntheses and biological evaluation of vinblastine congeners. Org Biomol Chem. (2003), 1(12), 2120-36.

67. von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small kinase inhibitor Cancer Res. (2003), 63(19): 6395-404.

68. Yoon KJ, Krull EJ, Morton CL, Bornmann WG, Lee RE, Potter PM, Danks MK. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies Mol Cancer Ther. (2003), 2(11): 1171-81.

10 69. Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A. (2003), 100(21): 12444-12449.

70. Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W, Gregor P, Reis CA, Clausen H, Danishefsky SJ, Livingston PO.A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol Immunother. (2003), 52(10), 608-616.

71. Lee MD, Antczak C, Li Y, Sirotnak FM, Bornmann WG, Scheinberg DA. A new human peptide deformylase inhibitable by actinonin. Biochem Biophys Res Commun. (2003), 312(2), 309-315.

72. Finn, R. D.; Qiao, J.; Nacca, A.; Sheh, Y.; Lom, C.; Balatoni, J.; Cai, S.; Bornmann, W.; Pentlow, K. Improved yields of iodine-124 from the enriched tellurium-124 dioxide /aluminum oxide target, AIP Conference Proceedings (2003), 680(Application of Accelerators in Research and Industry), 1121-1124.

73. Deckert PM, Bornmann WG, Ritter G, Williams C Jr, Franke J, Keilholz U, Thiel E, Old LJ, Bertino JR, Welt S. Specific tumour localisation of a huA33 antibody-- carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. Int J Oncol. (2004), 24(5), 128912-95.

74. Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, Ivanova A, Ageyeva L, Tourkova V, Balatoni J, Bornmann W, Blasberg R, Gelovani Tjuvajev J. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging. (2004), 31(5), 740-51.

75. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. (2004), 45(3), 366-373.

76. Cherukuri A, Carter RH, Brooks S, Bornmann W, Finn R, Dowd CS, Pierce SK. B cell signaling is regulated by induced palmitoylation of CD81. J Biol Chem. (2004), 279(30), 31973-31982.

77. Swimm A, Bommarius B, Li Y, Cheng D, Reeves P, Sherman M, Veach D, Bornmann W, Kalman D. Enteropathogenic E. coli Use Redundant Tyrosine Kinases to Form Actin Pedestals. Mol Biol Cell. (2004), 15(8), 3520-3529.

78. Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.Leukemia. 2004), 18(8), 1352-1356.

79. Yuan RR, Wong P, McDevitt MR, Doubrovina E, Leiner I, Bornmann W, O'Reilly R, Pamer EG, Scheinberg DA. Targeted deletion of T cell clones using alpha emitting suicide MHC tetramers. Blood. (2004), 104(8), 2397-2402.

11 80. Deng X, Hofmann ER, Villanueva A, Hobert O, Capodieci P, Veach DR, Yin X, Campodonico L, Glekas A, Cordon-Cardo C, Clarkson B, Bornmann WG, Fuks Z, Hengartner MO, Kolesnick R. Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nat Genet.( 2004), 36(8), 906-912.

81. von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screen for resistance of Bcr-Abl- positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.Blood. (2005), 105(4), 1652-1659.

82. Lee MD, She Y, Soskis MJ, Borella CP, Gardner JR, Hayes PA, Dy BM, Heaney ML, Philips MR, Bornmann WG, Sirotnak FM, Scheinberg DA. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.J Clin Invest. (2004), 114(8), 1107-1116.

83. Park HJ, Ahn KJ, Ahn SD, Choi E, Lee SW, Williams B, Kim EJ, Griffin R, Bey EA, Bornmann WG, Gao J, Park HJ, Boothman DA, Song CW. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.Int J Radiat Oncol Biol Phys. (2005), 61(1), 212-219.

84. Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL. PD166326, a novel tyrosine kinase inhibitor, has greater anti-leukemic activity than imatinib in a murine model of chronic myeloid leukemia.Blood. (2005), 105(10), 3995-4003.

85. Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med.(2005), 11(7), 731-739.

86. Ough M, Lewis A, Bey EA, Gao J, Ritchie JM, Bornmann W, Boothman DA, Oberley LW, Cullen JJ. Efficacy of beta-Lapachone in Pancreatic Cancer Treatment: Exploiting the Novel, Therapeutic Target NQO1.Cancer Biol Ther. (2005), 4(1) 95-102

87. Spees WM, Gade TP, Yang G, Tong WP, Bornmann WG, Gorlick R, Koutcher JA. An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle.Clin Cancer Res. (2005), 11(4), 1454-1461

88. Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, Misico RI, Arzac GM, Burton G, Bornmann WG, Sutton D, Gao J, Boothman DA. Development of {beta}- lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clin Cancer Res. (2005), 11(8), 3055-3064.

89. Spassova MK, Bornmann WG, Ragupathi G, Sukenick G, Livingston PO, Danishefsky SJ. Synthesis of Selected Le(Y) and KH-1 Analogues: A Medicinal Chemistry Approach to Vaccine Optimization.J Org Chem.( 2005), 70(9), 3383-3395

90. Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, Larson SM. Synthesis and in vitro examination of [(124)I]-, [(125)I]- and [(131)I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl Med Biol. (2005), 32(4), 313-321. 12

91. Samudio I, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann W, Ying Y, Evans R, Contractor R, Andreeff M. A Novel Mechanism of Action of Methyl-2-cyano-3,12 Dioxoolean-1,9 Diene-28-oate: Direct Permeabilization of the Inner Mitochondrial Membrane to Inhibit Electron Transport and Induce Apoptosis. Mol Pharmacol (2006), 69(4), 1182-1193.

92. O’Brian CA, Chu F, Bornmann WG, Maxwell DS. Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery? Expert Rev Anticancer Ther. (2006), 6(2), 175-186.

93. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunnker K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006), 66(7), 3773-3781.

94. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han DM, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KSC. Early detection of chemoradioresponse in esophageal carcinoma by 3 '-deoxy-3 '-H-3-fluorothymidine using preclinical tumor models. Clinical Cancer Research (2006), 12 (15), 4590-4597.

95. Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen, SM. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther (2006), 5(5):1325-1334

96. Wendel HG, de Stanchina E, Cepero E, Ray S. Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A. (2006), 103(19), 7444-7449.

97. Azam M, Nardi V, Shakespeare WC, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GZ. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A, (2006), 103(24), 9244-9249.

98. Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther. (2006), 5(5):1325-1334.

99. Pal A, Glekas A, Doubrovin M, Balatoni J, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, Finn R, Larson SM, Bornmann W, Gelovani JG.Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol. (2006), 8(5), 262-277.

100. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J.Pyridone 6, a pan-janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.Cancer Res. (2006), 66(19), 9714-9721.

13 101. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M.Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle. (2006), 5(23), 2778-2786.

102. Bommarius B, Maxwell D, Swimm A, Leung S, Corbett A, Bornmann W, Kalman D. Enteropathogenic Escherichia coli Tir is an SH2/3 ligand that recruits and activates tyrosine kinases required for pedestal formation. Mol Microbiol. (2007), 63(6), 1748- 1768.

103. Bartholomeusz G, Talpaz M, Bornmann W, Kong LY, Donato NJ. Degrasyn Activates Proteasomal-Dependent Degradation of c-Myc. Cancer Res. (2007), 67(8), 3912-3918.

104. Fernandez A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W, Lopez-Berestein G. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res. (2007), 67(9), 4028-4033.

105. Mukhopadhyay U, Pal A, Gelovani JG, Bornmann W, Alauddin MM. of 2'-deoxy-2'-[(18)F]-fluoro-5-methyl-1-beta-l-arabinofuranosyluracil ([(18)F]-l-FMAU) for PET. Appl Radiat Isot. (2007), 65(8), 941-946.

106. Berishaj M, Gao SP, Leslie K, Al-Ahmadie H, Gerald WL, Bornmann W, Bromberg JF. Stat3 is tyrosine phosphorylated through the IL-6/gp130/Jak pathway in breast cancer. Breast Cancer Res. (2007), 9(3):R32

107. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, Boothman DA. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A. (2007), 104(28), 11832-11837.

108. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. (2007), 67(22), 10976-10983.

109. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. (2007), 117(12), 3846-3856.

110. Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. (2007), 117(12), 4044-4054.

111. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M. Sorafenib induces apoptosis of AML cells via Bim- mediated activation of the intrinsic apoptotic pathway.Leukemia. (2008), 22(4), 808-818.

14 112. Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronic myelogenous leukemia cells.Blood. (2008), 111(7), 3821-3829

113. Yamaguchi H, Ding Y, Lee JF, Zhang M, Pal A, Bornmann W, Yan DH, Hung MC. Interferon-inducible protein IFIXalpha inhibits cell invasion by upregulating the metastasis suppressor maspin. Mol Carcinog. (2008), 47(10), 739-743.

114. Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ. Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase. Structure. (2008), 16(3), 460-467.

115. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. (2008), 68(9), 3413-3420.

116. Nishii R, Volgin AY, Mawlawi O, Mukhopadhyay U, Pal A, Bornmann W, Gelovani JG, Alauddin MM. Evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-methyl-1-beta-L: - arabinofuranosyluracil ([(18)F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [ (18)F]-D: -FMAU and [ (18)F]FLT. Eur J Nucl Med Mol Imaging. (2008), 35 (5), 990-998

117. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ. Association Between Imatinib-Resistant BCR-ABL Mutation- Negative Leukemia and Persistent Activation of LYN Kinase. J Natl Cancer Inst. (2008), 100(13), 926-939.

118. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2- overexpressing breast cancer cells. Mol Cancer Ther. (2008), 7(7), 1846-1850.

119. Sankaranarayanapillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, Bornmann WG, Soghomonyan S, Pal A, Ramirez MS, Webb D, Kaluarachchi K, Gelovani JG, Ronen SM. Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method. Mol Imaging. (2008), 7(2), 92-100.

120. Wagner MW, Li LS, Morales JC, Galindo CL, Garner HR, Bornmann WG, Boothman DA. Role of c-Abl Kinase in DNA Mismatch Repair-dependent G2 Cell Cycle Checkpoint Arrest Responses.J Biol Chem. (2008), 283(31), 21382-21393.

121. Ghosh, P.; Pal, A.; Shavrin, A.; Bornmann, W.; Gelovani, J. G.; Alauddin, M. M. Synthesis of N3-substituted thymidine analogues for measurement of cellular kinase activity. Medicinal Chemistry (2008), 4(5), 503-512.

122. Dong Y, Chin SF, Blanco E, Bey EA, Kabbani W, Xie XJ, Bornmann WG, Boothman DA, Gao J. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res. (2009), 15(1), 131-139.

15 123. Najjar AM, Nishii R, Maxwell DS, Volgin A, Mukhopadhyay U, Bornmann WG, Tong W, Alauddin M, Gelovani JG. Molecular-Genetic PET Imaging Using an HSV1-tk Mutant Reporter Gene with Enhanced Specificity to Acycloguanosine Nucleoside Analogs. J Nucl Med. (2009), 50(3), 409-416.

124. Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, Nishii R, Alauddin M, Mukhopadhay U, Peng Z, Bornmann W, Gelovani J. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. (2009), 8(4), 947-958.

125. Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit Inhibitor APcK110 Induces Apoptosis and Inhibits Proliferation of Acute Myeloid Leukemia Cells. Cancer Res. (2009), 69(9), 3910- 3917.

126. Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther.(2009), 8(5), 1157-1168.

127. Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC. Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma. Clin Cancer Res. (2009), 15(10), 3472-3483.

128. Edler MC, Yang G, Jung MK, Bai R, Bornmann WG, Hamel E. Demonstration of microtubule-like structures formed with (-)-rhazinilam from purified tubulin outside of cells and a simple tubulin-based assay for evaluation of analog activity. Arch Biochem Biophys. (2009), 487(2), 98-104.

129. Flores LG, Bertolini S, Yeh HH, Young D, Mukhopadhyay U, Pal A, Ying Y, Volgin A, Shavrin A, Soghomonyan S, Tong W, Bornmann W, Alauddin MM, Logsdon C, Gelovani JG.; Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT. PLoS One.( 2009), 4(11):e7977.

130. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. (2010), 120(1), 142-156.

131. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res.( 2010), 16(1),184-194.

132. Doubrovin M, Kochetkova T, Santos E, Veach DR, Smith-Jones P, Pillarsetty N, Balatoni J, Bornmann W, Gelovani J, Larson SM. (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. J Nucl Med. (2010), 51(1), 121-129. 16

133. Wu J, Meng F, Ying Y, Z Peng, Daniels L, Bornmann WG, Quintás-Cardama A, Roulston D, Talpaz M, Peterson LF, et al. ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells Leukemia (2010), 24(4), 869-872.

134. Swimm AI, Bornmann W, Jiang M, Imperiale MJ, Lukacher AE, Kalman D. Abl-family Tyrosine Kinases Regulate Sialylated Ganglioside Receptors for Polyomavirus. J Virol. (2010), 84(9), 4243-4251

135. Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, Kessinger CW, Carnevale KA, Bornmann WG, Boothman DA, Gao J. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. (2010), 70(10), 3896-3904.

136. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan- Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. (2011), 2995), 1094-1097.

137. Robertson, F.M., Woodward, W.A., Pickei, R., Ye, Z., Bornmann, W., Pal, A., Peng, Z., Hall, C.S., Cristofanilli, M. Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids, Cancer (2010) 116 (11, SUPPL.), 2760-2767

138. McNulty S, Bornmann W, Schriewer J, Werner C, Smith SK, Olson VA, Damon IK, Buller RM, Heuser J, Kalman D. Multiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesis. PLoS One. (2010), 5(5):e10884.

139. Ying Y, Ghosh P, Guo L, Pal A, Mukhapadhyay U, Peng Z, Yeh HH, Bertolini S, Flores LG, Young D, Volgin A, Soghomonyan S, Bornmann W, Logsdon C, Alauddin MM, Gelovani JG. Synthesis and Ex Vivo Autoradiographic Evaluation of Ethyl-beta-D: - galactopyranosyl-(1,4')-2'-deoxy-2'-[(18)F]fluoro-beta-D: -glucopyranoside-A Novel Radioligand for Lactose-Binding Protein: Implications for Early Detection of Pancreatic Carcinomas with PET. Mol Imaging Biol. (2011), 13(3), 536-546.

140. Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther. (2010), 9(7), 2026-2036.

141. Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung MC. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr- 1-mediated Bim upregulation. Oncogene. (2010), 29(41), 5619-5629.

142. Reeves PM, Smith SK, Olson VA, Thorne SH, Bornmann W, Damon IK, Kalman D.Variola and monkeypox utilize conserved mechanisms of virion motility and release that depend on Abl- and Src-family tyrosine kinases. J Virol. (2011), 85(1), 21–31.

143. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis. Cancer Res. (2010), 70(22), 9265-9276. 17

144. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo. PLoS One. (2010), 5(11):e14124.

145. Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA. Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy.Clin Cancer Res. (2011), 17(2), 275-285.

146. Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood. (2011), 117(11), 3151-3162.

147. Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA.STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17. Cancer Res. (2011), 71(10), 3658-3668.

148. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. (2011), 117(19), 4424-4438.

149. Schwartz, David L.; Bankson, James; Bidaut, Luc; He, Yi; Williams, Ryan; Lemos, Robert; Thitai, Arun Kumar; Oh, Jung-Hwan; Volgin, Andrei; Soghomonyan, Suren; HIF- 1-Dependent Stromal Adaptation to Ischemia Mediates In Vivo Tumor Radiation Resistance Mol Cancer Ther. (2011), 9(3), 259-270.

150. Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal. (2011), 23(12), 2076-2085.

151. Peng Z, Pal A, Han D, Wang S, Maxwell D, Levitzki A, Talpaz M, Donato NJ, Bornmann W. Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. Bioorg Med Chem. (2011), 19(23), 7194-7204.

152. Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. (2012), 26(4), 778-787..

153. Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D.Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis. Cell Host Microbe. (2011), 10(5), 475- 485.

18 154. García M, Cooper A, Shi W, Bornmann W, Kalman D, and Nabel G J. Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase. Sci Transl Med. (2012), 4(123), 123ra24

155. Myers AL, Zhang Y-P, Kramer MA, Bornmann WG, Kaseb A, Yang P and Tran HT, A Practical Synthesis and X-ray Crystallographic Analysis of Dithymoquinone, a Photodimer of Thymoquinone, Letters in Organic Chemistry, (2012),9(10), 762-766 156. Arumugam T, Ramachandran V, Maxwell D, Bornmann WG, Logsdon CD.Designing and Developing S100P Inhibitor 5-methyl Cromolyn (C5OH) for Pancreatic Cancer Therapy.Mol Cancer Ther. (2013), 12(5), 654-662. 157. Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R. Binding partners for curcumin in human schwannoma cells: Biologic Implications. Bioorg Med Chem. (2013), 21(4), 932-939. 158. Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, Bornmann WG, Yu-Lee LY, Gallick GE, Zhang W, Lin SH, Kuang J RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B. Oncogene. 2014 May 1;33(18):2385-94. 159. Vanderslice P, Biediger RJ, Woodside DG, Brown WS, Khounlo S, Warier ND, Gundlach CW, Caivano AR, Bornmann WG, Maxwell DS, McIntyre BW, Willerson JT, Dixon RA Small Molecule Agonist of VLA-4 Integrin Induces Progenitor Cell Adhesion. J Biol Chem. (2013), 288(27):19414-19428. 160. Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson V, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, Buchsbaum DJ, Spitz DR, Gao J, Boothman DA. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol Cancer Ther. (2013), 12(10), 2110-2120. 161. Sun D, Bhanu Prasad BA, Schuber PT Jr, Peng Z, Maxwell DS, Martin DV, Guo L, Han D, Kurihara H, Yang DJ, Gelovani JG, Powis G, Bornmann WG. Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase. Bioorg Med Chem. (2013), 21(17), 5182- 5187. 162. Pal A, Peng Z, Schuber Jr. PT, Prasad BAB, Bornmann, WG. Asymmetric Synthesis of the C1-C6 Portion of the Psymberin Using an Evans Chiral Auxiliary: Tetrahedron Lett. (2013), 54 (41), 5555-5557. 163. Maxwell DS, Sun D, Peng Z, Martin DV, Bornmann WG. Synthesis of a Macrocycle Based on Linked Amino Acid Mimetics (LAAM): Tetrahedron Lett. (2013), 54(43), 5799-5801.

164. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. ( 2013), 123(5), 2119-2130 19 165. Arumugam T, Ramachandran V, Sun D, Peng Z, Pal A, Maxwell DS, Bornmann WG, Logsdon CD. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Mol Cancer Ther. (2013), 12(5), 654-662

166. Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K. Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation. PLoS One. 2013 Oct 16;8(10):e77262.

167. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 1;19(3):657-67

168. Pal A, Sung B, Bhanu Prasad BA, Schuber PT Jr, Prasad S, Aggarwal BB, Bornmann WG. Curcumin Glucuronides: Assessing the Proliferative Activity Against Human Cell Lines: Bioorg Med Chem. Bioorg Med Chem. 2014 Jan 1;22(1):435-9

169. Peng Z, Maxwell DS, Sun D, Pal A, Wang A, Balatoni J, Ghosh P, Lim ST, Pal A, Wang S, Volgin A, Shavrin A, Alauddin M, Gelovani JG, Bornmann WG. Imatinib Analogs as Potential Agents for PET Imaging of Bcr-Abl/c-Kit expression. Bioorg Med Chem. 2014;22(1):623-32.

170. Peng Z, Maxwell DS, Ying Y, Schuber Jr. PT, Prasad BAB, Gelovani JG, Yung W-KA, Bornmann, WG. Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies: Tetrahedron, 2014;70(4):984-90.

171. Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT Jr, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, Donato NJ, Bornmann WG. Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).Bioorg Med Chem. 2014 Feb 15; 22(4):1450-8.

172. Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Bentle MS, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, Morales JC, Motea EA, Bornmann WG, Yordy J, Boothman DA. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs. Antioxid Redox Signal. 2014 Jul 10;21(2):237-50

173. Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, Schober WD, Smith P, Guichard S, Konopleva M, Andreeff M. Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myeloid Leukemia Cells. Mol Cancer Ther. 2014 2014 Jul;13(7):1848-59.

174. Caruso JA, Campana R, Wei C, Su CH, Hanks AM, Bornmann WG, Keyomarsi K. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells. Cell Cycle. 2014 Aug 15;13(16):2587-99

175. Napier RJ, Norris BA, Swimm A, Giver CR, Harris WAC, Laval J, Napier BA, Patel G, Crump R, Peng Z, Bornmann W, Pulendran B, Buller RM, Weiss DS, Tirouvanziam R, 20 Waller EK, and Kalman D, Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity PLOS Pathogens 2015 Mar 30;11(3):e1004770.

176. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer. Li LS, Reddy S, Lin ZH, Liu S, Park H, Chun SG, Bornmann WG, Thibodeaux J, Yan J, Chakrabarti G, Xie XJ, Sumer BD, Boothman DA, Yordy JS. Mol Cancer Ther. 2016, (7):1757-67.

177. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Velez J, Pan R, Lee JT, Enciso L, Suarez M, Duque JE, Jaramillo D, Lopez C, Morales L, Bornmann W, Konopleva M, Krystal G, Andreeff M, Samudio I. Oncotarget. 2016, 7(32):51435-51449.

178. SF2312 is a natural phosphonate inhibitor of enolase. Leonard PG, Satani N, Maxwell D, Lin YH, Hammoudi N, Peng Z, Pisaneschi F, Link TM, Lee GR, Sun D, Prasad BA, Di Francesco ME, Czako B, Asara JM, Wang YA, Bornmann W, DePinho RA, Muller FL. Nat Chem Biol. 2016, (12):1053-1058.

Manuscripts under Preparation

1. Peng Z, Maxwell DS, Ying Y, Ghosh P, Alauddin M, Gelovani JG, Bornmann WG. Synthesis of [18F]-Dasatinib Analog for Pet Imaging: Manuscript under preparation.

2. Peng Z, Maxwell DS, Gao L, Kim W-Y, Hong WK, Lee H-Y, Bornmann WG. The Synthesis and anticancer Activity Evaluation of Deguelin Analogs: Manuscript under preparation

3. Peng Z, Maxwell DS, Han D, Guo L, Samudio I, Yang D, Andreeff M, Bornmann WG. PET Imageable Bcl-2 inhibitor 124I-ABT-737. Manuscript under preparation.

4. Maxwell DS, Sun D, Peng Z, McConkey D, Bornmann WG. Design and optimization of a new series of HSP-70 Inhibitors for use in the treatment of pancreatic cancer: Manuscript under preparation.

5. Sun D, Maxwell DS, Peng Z, Holla V, DuBois R, Menter D, Bornmann WG. Design and Synthesis of PPARδ Antagonists Based on a Two-Stage Similarity Search. Manuscript under preparation.

6. Napier RJ, Norris BA, Swimm A, Give C, Laval J, Harris W, Napier BA, Patel G, Peng Z, Bornmann WG, Shinnick T, Pulendran B, Buller M, Weiss D, Tirouvanziam R, Waller E, and Kalman D, Imatinib-mesylate induces granulopoiesis and an anti-infectious immune response. Manuscript under preparation.

7. Peng Z, Maxwell DS, Pal A, Kurihara H, Yang D, Gelovani JG, Bornmann WG. Synthesis and Radiolabeling of SAHA Analog for Radio Imaging of HDAC Expression- 21 Occupancy in Tumors during Molecular-Targeted Therapy of Cancer. Bioorg Med Chem. , Manuscript under preparation.

PATENTS

1. Scheinberg, David; Bornmann, William G.; Sirotnak, Francis; Scher, Howard; Vidal, Ephraim; Borella, Christopher. Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and derivatives. U.S. Pat. Appl. Publ. (2005), 31 pp., Cont.-in-part of U.S. Ser. No. 603,953. US 2005272667 A1 20051208

2. Kalman, Daniel; Bornmann, William Gerard; Sherman, Melanie Anne; Reeves, Patrick Michael; Swimm, Alyson Irene. Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection. PCT Int. Appl. (2005), 65 pp. WO 2005072826 A2 20050811

3. Scheinberg, David A.; Lee, Mona D.; Sirotnak, Francis M.; Antczak, Christophe; Bornmann, William G.. Characterization of actinonin-inhibitable human peptide deformylase, siRNA inhibiting peptide deformylase expression, and use of the as a target of anti-cancer therapies. PCT Int. Appl. (2005),135 pp. WO 2005044995 A2 20050519

4. Koutcher, Jason; Bornmann, William G.. Fluoromethotrexates and uses in treating cancer and in assaying for tumor sensitivity or resistance to methotrexate therapy. PCT Int. Appl. (2004), 69 pp. WO 2004071463 A2 20040826

5. Veach, Darren R.; Bornmann, William; Clarkson, Bayard D.; Von Bubonoff, Nikolas; Duyster, Justus. Preparation of aminopyridopyrimidinones as tyrosine kinase inhibitors for treatment of cancer. PCT Int. Appl. (2004), 146 pp. WO 2004063195 A1 20040729

6. Vera, Juan Carlos; Bornmann, William G.; Zamora-Leon, Pilar; Golde, David W.; Spassova, Maria. Compositions and method for evaluating tissue for the presence of cancer cells. PCT Int. Appl. (1997), 31 pp. WO 9732590 A1 19970912

7. Danishefsky, Samuel; Depew, Kristopher; Marsden, Stephen P.; Bornmann, William; Woo, Jonathan C. G.; Chou, Ting-Chao; Schkeryantz, Jeffrey; Zatorski, Andrej. synthesis and biological activity of analogs of n-acetylardeemin for use as antitumor agents. PCT Int. Appl. (1997), 134 pp. WO 9718215 A1 19970522

8. Danishefsky, Samuel J.; Bornmann, William G.; Queneau, Yves; Magee, Thomas V.; Krol, Walter J.; Masters, John J.; Jung, David K. Total synthesis of taxol and analogs. U.S. (1996), 83 pp., Cont.-in-part of U.S. 5,416,225. US 5488116 A 19960130

9. Danishefsky, Samuel J.; Bornmann, William G.; Queneau, Yves; Magee, Thomas V.; Krol, Walter J.; Masters, John J.; Jung, David K. Total synthesis of taxol and its analogs. PCT Int. Appl. (1995), 313 pp. WO 9512567 A1 19950511

22 10. Danishefsky, Samuel J.; Bornmann, William G.; Shen, Wang; Coburn, Craig A. Methods of preparation of camptothecin analogs. U.S. (1995), 56 pp. Cont.-in-part of U.S. Ser. No. 919,188. US 5391745 A 19950221

11. Danishefsky, Samuel J.; Bornmann, William G.; Shen, Wang; Coburn, Craig A. Preparation of camptothecin analogs as neoplasm inhibitors. PCT Int. Appl. (1994), 255 pp. WO 9411376 A1 19940526

12. Danishefsky, Samuel J.; Bornmann, William G.; Queneau, Yves; Magee, Thomas V.; Krol, Walter J. Total synthesis of taxol. PCT Int. Appl. (1993), 222 pp. WO 9320036 A1 19931014

13. Spriggs, David; Bornmann, William G.; Alteration of Gene Expression through the use of drugs which alter mRNA binding to Elongation Factor 1 alpha and other RNA binding protein. U.S. Provisional Application 10/102,593. 3/15/00

14. Kalman, Daniel; Bornmann, William Gerard. Methods of use of non-ATP competitive tyrosine kinase inhibitors to treat pathogenic infection. PCT Int. Appl. (2007), 85pp. WO 2007002441 2007-01-04

15. Kalman, Daniel; Bornmann, William Gerard; Sherman, Melanie Anne; Reeves, Patrick Michael; Swimm, Alyson Irene. Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection. PCT Int. Appl. (2005), 65 pp. WO 2005072826 2005-08-11

16. Ronen, Sabrina M.; Gelovani, Juri G.; Bornmann, William G.; Pang, Jihai; Pal, Ashutosh; Tong, William P.; Maxwell, David S.; Sankaranarayanapillai, Madhuri. A fluorinated substrate for MRS-based assay for intracellular detection of histone deacetylase and monitoring HDAC inhibition, and preparation of HDAC inhibitors for therapeutic use. PCT Int. Appl. (2007), 48pp. WO 2007124435 2007-11-01 17. Bornmann, William; Maxwell, David; Peng, Zhenghong; Guo, Liwei. Preparation of pyrimidines and imidazopyrazines as inhibitors of tyrosine kinases. PCT Int. Appl. (2008), 57pp. WO 2008030795 2008-03-13

18. Bornmann, William; Maxwell, David; Ying, Yunming; Han, Dongmei; Peng, Zhenghong; Gandhi, Varsha; Stellrecht, Christine. Preparation of heterocycle compounds as inhibitors of c-Met. PCT Int. Appl. (2008), 78pp. WO 2008030744 2008-03-13

19. Bornmann, William; Alauddin, Main; Gelovani, Juri; Ghosh, Pradip; Guo, Liwei; Han, Dongmei; Maxwell, David; Mukhopadhyay, Uday; Peng, Zhenghong; Shavrin, Aleksandr; Ying, Yunming. Preparation of radiolabeled imatinib derivatives for positron emission tomography imaging of cancer cells. PCT Int. Appl. (2008), 35pp. WO 2008024829 2008-02-28

20. Bornmann, William; Alauddin, Mian; Gelovani, Juri; Ghosh, Pradip; Guo, Liwei; Han, Dongmei; Maxwell, David; Mukhopadhyay, Uday; Peng, Zhenghong; Shavrin, Aleksandr; Ying, Yunming. disaccharide halo-radiolabeled markers and methods 23 of their synthesis and use in PET imaging of cancers. PCT Int. Appl. (2008), 14pp. WO 2008024830 2008-02-28

21. Bornmann, William; Alauddin, Mian; Gelovani, Juri; Ghosh, Pradip; Guo, Liwei; Han, Dongmei; Maxwell, David; Mukhopadhyay, Uday; Peng, Zhenghong; Shavrin, Aleksandr; Ying, Yunming; Pal, Ashutosh. Radio-halo-thymidines and methods of their synthesis and use in PET imaging of cancer cells. PCT Int. Appl. (2008), 33pp. WO 2008024826 2008-02-28

22. Donato, Nicholas J.; Maxwell, David; Talpaz, Moshe; Bornmann, William; Peng, Zhenghong; Pal, Ashutosh; Han, Dongmei; Wang, Shimei; Bartholomeusz, Geoffrey; Kapuria, Vaibhav. Tyrphostin derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as signaling protein modulators. PCT Int. Appl. (2008), 198pp. WO 2008005954 2008-01-10

23. Bornmann, William; Maxwell, David; Pal, Ashutosh; Peng, Zhenghong; Estrov, Zeev. Substituted 1H-pyrazolo[3,4-b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as c-kit inhibitors. PCT Int. Appl. (2008), 108pp. WO 2008005877 2008-01-10

24. Logsdon, Craig D.; Bornmann, William. Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products. U.S. Pat. Appl. Publ. (2009), 36pp., Cont.-in-part of U.S. Ser. No. 41,112. CODEN: USXXCO US 2009062319 A1 20090305 CAN 150:275546 AN 2009:270711 CAPLUS

25. Koo, Ja Seok; Bornmann, William; Maxwell, David. Method of cancer treatment with naphthol analogs. PCT Int. Appl. (2008), 69pp. CODEN: PIXXD2 WO 2008106248 A1 20080904 CAN 149:324037 AN 2008:1071190 CAPLUS

26. Fernandez, Ariel; Bornmann, William; Lopez-Berestein, Gabriel; Sanguino, Angela; Peng, Zhenghong. Preparation of pyrimidine-2-amine compositions related to wrapping of dehydrons. PCT Int. Appl. (2008), 104pp. CODEN: PIXXD2 WO 2008070350 A2 20080612 CAN 149:54016 AN 2008:698672 CAPLUS

27. Bornmann, William; Maxwell, David; Peng, Zhenghong; Guo, Liwei. Preparation of pyrimidines and imidazopyrazines as inhibitors of tyrosine kinases. PCT Int. Appl. (2008), 57pp. CODEN: PIXXD2 WO 2008030795 A2 20080313 CAN 148:355823 AN 2008:319885 CAPLUS

28. Bornmann, William; Maxwell, David; Ying, Yunming; Han, Dongmei; Peng, Zhenghong; Gandhi, Varsha; Stellrecht, Christine. Preparation of heterocycle compounds as inhibitors of c-Met. PCT Int. Appl. (2008), 78pp. CODEN: PIXXD2 WO 2008030744 A2 20080313 CAN 148:331694 AN 2008:317743 CAPLUS

29. Bornmann, William; Alauddin, Main; Gelovani, Juri; Ghosh, Pradip; Guo, Liwei; Han, Dongmei; Maxwell, David; Mukhopadhyay, Uday; Peng, Zhenghong; Shavrin, Aleksandr; Ying, Yunming. Preparation of radiolabeled imatinib derivatives for positron emission tomography imaging of cancer cells. PCT Int. Appl. (2008), 24 35pp. CODEN: PIXXD2 WO 2008024829 A2 20080228 CAN 148:285207 AN 2008:255723 CAPLUS

30. Bornmann, William; Alauddin, Mian; Gelovani, Juri; Ghosh, Pradip; Guo, Liwei; Han, Dongmei; Maxwell, David; Mukhopadhyay, Uday; Peng, Zhenghong; Shavrin, Aleksandr; Ying, Yunming. disaccharide halo-radiolabeled markers and methods of their synthesis and use in PET imaging of cancers. PCT Int. Appl. (2008), 14pp. CODEN: PIXXD2 WO 2008024830 A2 20080228 CAN 148:285421 AN 2008:253447 CAPLUS

31. Bornmann, William; Alauddin, Mian; Gelovani, Juri; Ghosh, Pradip; Guo, Liwei; Han, Dongmei; Maxwell, David; Mukhopadhyay, Uday; Peng, Zhenghong; Shavrin, Aleksandr; Ying, Yunming; Pal, Ashutosh. Radio-halo-thymidines and methods of their synthesis and use in PET imaging of cancer cells. PCT Int. Appl. (2008), 33pp. CODEN: PIXXD2 WO 2008024826 A2 20080228 CAN 148:285425 AN 2008:253438 CAPLUS

32. Donato, Nicholas J.; Maxwell, David; Talpaz, Moshe; Bornmann, William; Peng, Zhenghong; Pal, Ashutosh; Han, Dongmei; Wang, Shimei; Bartholomeusz, Geoffrey; Kapuria, Vaibhav. Tyrphostin derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as signaling protein modulators. PCT Int. Appl. (2008), 198 pp. CODEN: PIXXD2 WO 2008005954 A2 20080110 CAN 148:144655 AN 2008:43308 CAPLUS

33. Bornmann, William; Maxwell, David; Pal, Ashutosh; Peng, Zhenghong; Estrov, Zeev. Substituted 1H-pyrazolo[3,4-b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as c-kit inhibitors. PCT Int. Appl. (2008), 108pp. CODEN: PIXXD2 WO 2008005877 A2 20080110 CAN 148:144761 AN 2008:42473 CAPLUS

34. Logsdon, Craig D.; Bornmann, William Methods of treating cancer by inhibiting the interaction between S100 protein and the receptor for advanced glycation end- products U.S. Pat. Appl. Publ. (2011), US 20110195924 A1 20110811

35. Kalman, Daniel.; Bornmann, William Kinase Inhibitors for preventing or treating pathogen infection and method of use thereof. U.S. Pat. Publ. (2012), US 20120302565-A1

36. Bornmann, William; Maxwell, David; Pal, Ashutosh; Peng, Zhenghong; Phan, Lan; Tamayo, Archito; Ford, Richard. WO2014160339A1 Compounds For Treating Inflammatory And Hyperproliferative Diseases.

37. Florian Muller F, Maxwell DS, Bornmann WG, Lin Y, Prasad B, Peng Z, Sun D, Satani N, DiFrancesco ME, DePinho R, Czako B WO2016145113 A1 Enolase Inhibitors and Methods of Treatment Therewith

INVENTION DISCLOSURES SUBMITTED

(1) Bornmann, W.; Peng, Z.; Maxwell, D.; Donato, N. J.; Pal, A. et al. SIGNALING 25 PROTEIN MODULATORS AS THERAPEUTIC AGENTS. In Provisional Patent Application UTSC:973USP1 MDA06-135, 2006. (2) Bornmann, W.; Peng, Z.; Maxwell, D.; Donato, N. J.; Pal, A. et al. SIGNALING PROTEIN MODULATORS AS THERAPEUTIC AGENTS. In Provisional Patent Application UTSC:971USP1 MDA06-113, 2006 (3) Bornmann, W.; Maxwell, D.; Peng, Z.; Pal, A.; Ying, Y. et al. Radiohalogents and Methods of their Synthesis and Use in PET Imaging of Cancers. In Provisional Patent Application 60/823,324 MDA06-125 (combined with MDA06-126, 06-127, 06-129, 06- 140), 2006. (4) Bornmann, W.; Maxwell, D. Protein Kinase C Inhibitors. In Provisional Patent Application MDA05-137 60/763,825, 2006. (5) Bornmann, W. Detection of Histone Deacetylase Inhibition. In Provisional Patent Application MDA06-075 60/745,361, 2006. (6) Fernández, A.; Peng, Z.; Sanguino, A.; Ozturk, E.; Bornmann, W. et al. Molecularly engineered specificity in anti-cancer activity: Cell-line and molecular assays translating a structural discriminator. In Provisional Patent Application MDA06-048 60/863,255, 2006. (7) Bornmann, W.; Peng, Z.; Gao, L.; Lee, H.-Y.; Kim, W.-Y. Novel Strategy for Lung Cancer Chemoprevention and Treatment Using Deguelin Analogs of Akt Inhibitors. In patent application file pending MDA06-080, 2006. (8) Bornmann, W.; Pal, A.; Peng, Z. New Synthesis Process of Lapinib (an EGFR and ErbB- 2 Dual Tyrosine Kinase Inhibitor Under Clinical Trial. In Provisonal Patent Pending MDA07048, 2006. (9) Bornmann, W.; Maxwell, D.; Han, D.; Guo, L. Synthesis of [124]I-ABT-737, a New Radiotracer for PET Imaging of Bcl-2 Expression. In Provisional Patent application pending MDA06-128, 2006. (10) Bornmann, W.; Pal, A. Novel Agent for In Vivo PET Imaging of Tumor Proliferation and Measurement of Thymidine Kinase (TK1) and Deoxycytidien Kinase (dCK) Activity. In Provisional Patent Pending MDA07-029, 2006.

RECENT PRESENTATIONS

1. Mundy BP, Bornmann WG, Lipkowitz KB. The Cope rearrangement as a synthetic methodology. 33rd American Chemical Society Northwest Regional Meeting, 1978.

2. Mundy BP, Bornmann WG. A new synthesis of Brevicomin. 33rd American Chemical Society Northwest Regional Meeting, 1978.

3. Bornmann WG, Kuehne ME, Parsons WH. Synthesis of Cephalotaxine. 194th American Chemical Society National Meeting, Aug. 30, 1987.

4. Bornmann WG, Kuehne ME, Borman LS. Total Synthesis of Four Vinblastine Congeners and their biochemical evaluation. 22nd National Medicinal Chemistry Symposium, Austin, TX, Jul. 29 - Aug. 2, 1990.

5. Bornmann WG, Kuehne ME. The Total Syntheses of (±)-Coronaridine, (±)-Ibogamine, (±)-Pseudotabersonine, (±)-Ibophyllidine, (±)-Iboxyphyllline, (±)-Catharanthine, Vinamidine and Vinblastine via a common precursor. Paper No. 215. 200th American Chemical Society National Meeting, Washington, DC, Aug. 26-31, 1990. 26

6. Bornmann WG, Borman LS, Kuehne ME. The Total Synthesis of Four Vnblastine Congeners and their biological evaluation. Poster no. 13. 11th Regional Cancer Research Symposium, sponsored by Vermont Regional Cancer Center, Burlington, VT, Nov. 30 - Dec. 1, 1990.

7. Bornmann WG. Total Syntheses of Vinblastine, 20-Deoxyvinblastine and Cephalotaxine. Cancer Therapy and Research Center, The University of Texas Health Sciences Center, San Antonio, TX, Sept. 28, 1990.

8. Bornmann WG, Kuehne ME. Studies toward the Total asymmetric synthesis of 15, 20- Dihydrosecodine, Tetrahydropresecamine, and Tetrahydrosecamine. International Research Congress on Natural Products. 32nd Annual Meeting, American Society of Pharmacognosy, Jul. 21 - 26, 1991.

9. Bornmann WG, Kuehne ME. Versatility in natural products synthesis. The Total Syntheses of (±)- pseudo-tabersonine, (±)-Catharanthine, (±)-Cornaridine, (±)- Iboxyphylline, (±)-Ibophyllidine, Vinaminoline and Vinblastine via a common intermediate. International Research Congress on Natural Products. 32nd Annual Meeting, American Society of Pharmacognosy; Jul. 21 - 26, 1991.

10. Bornmann WG, Kuehne ME. Total formal synthesis of (±)-Andranginine and (±)-epi- Andranginine. Poster B-41. 32nd National Organic Chemistry Symposium, The University of Minnesota, Minneapolis, MN, Jun. 16 - 20, 1991.

11. Bornmann WG, LeBoulluec KL, Kuehne ME. Total Synthesis of 20'-methyl-20'- desethyl-20'-deoxyvinblastine, 20'-methyl-20'-desethyl-20'-deoxyvincovaline, 20'- methyl-20'-desethyl-20'-deoxyleurosidine, and 20'-methyl-20'-epi-20'-desethyl-20'- deoxyvincovaline. Poster A-31. 32nd National Organic Chemistry Symposium, The University of Minnesota, Minneapolis, MN, Jun. 16 - 20, 1991.

12. Bornmann WG. A second generation approach to the Total synthesis of Vinblastine, Vincovaline, Leurosidine, and 20'-epi-Vincovaline. 13th International Congress of Heterocyclic Chemistry, Oregon State University,Aug. 11-16, 1991.

13. Bornmann WG, Kuehne ME. The Asymmetric Total synthesis of (+) and (-) Pandoline, (+) and (-) epi Pandoline, and (+) and (-) Pseudotabersonine. 201st American Chemical Society National Meeting, Atlanta, GA, Apr. 14 - 19, 1991.

14. Bornmann WG, Kuehne ME. Total Asymmetric Syntheses of 15,20-Dihydrosecodine, Tetrahydropresecamine, and Tetrahydrosecamine. Poster. The Fourth Chemical Congress of North America, 202nd American Chemical Society National Meeting, New York, NY, Aug. 25 - 30, 1991.

15. Bornmann WG. New Aspects in the Total Synthesis of Vinblastine. Second and third generation approaches. Second Anticancer Drug Discovery and Development Symposium; Wayne State University School of Medicine; Jun. 27 - 29, 1991.

16. Bornmann WG, Isaacs RCA, Magee TV, Queneau Y, Krol WJ, DiGrandi MJ, Danishefsky SJ. New Functionalized intermediate containing the ACD substructure of 27 taxol. Second National Cancer Institute Workshop on Taxol and Taxus; Alexandria, VA, Sept. 23 - 24, 1992.

17. Bornmann WG. Total Synthesis of the dimeric indole alkaloids Vinblastine and Vincristine: first, second and third generation approaches,. The City University of New York (CUNY)-Hunter College, New York, NY, Nov. 1992.

18. Bornmann WG, Shen W, Chou T, Coburn C, Danishefsky SJ. Inhibition of DNA Topoisiomerase I and tumor cell growth by new Camptothecin synthetic congeners. 84th Annual Meeting of the American Association of Cancer Research, Orlando, FL. May 19-22, 1993.

19. Bornmann WG, Krol WJ, Queneau Y, Danishefsky SJ. Nozaki-Kishi Reaction of Crotonates as a Source of Complex Dienophiles: Application to the B-SecoTaxane Series. 33rd National Organic Chemistry Symposium, Montana State University, Bozeman, MT, Jun. 13-17,1993.

20. Bornmann WG. Synthetic Approaches towards the total syntheses of the anticancer drugs Taxol and Camptothecin. The City University of New York (CUNY)-Queens College, NY, Oct. 20,1993.

21. Kuehne ME, Bornmann WG, Frasier DA, Marko I, Matson PA, Mulamba T, Borman LS Exon C. Syntheses and biological evaluation of vinblastine congeners Second International Interface of Clinical and Laboratory Responses to Anticancer Drugs, Marseille, France, Apr. 2-4, 1992

22. Kothari PJ, Bornmann WG, Finn RD,Vera JC, Golde DW, Larson SM. Multi-millicurie Preparation of 6-[18F]Fluoro-6-deoxy-L-ascorbic Acid via Nucleophilic Displacement with 18F-Labelled Fluoride. 11th International Symposium on Radiopharmaceutical Chemistry (6th Workshop on Targetry and Target Chemistry), The University of British Columbia, Vancover, BC, Canada, Aug. 13-18, 1995.

23. Bornmann WG. Synthetic Approaches to the Bis-Indole Alkaloids Vinblastine and Presecamine. New York University, New York, NY, Sept. 29, 1995.

24. Bornmann WG. Synthetic Approaches to the Bis-Indole Alkaloids Vinblastine and Presecamine. The University of Wisconsin-Milwaukee, Milwaukee, WI, Jul.26, 1995.

25. Bornmann WG, Live D, Wu R, Silks LA. Strategies for Preparation and NMR of C-13 Labeled Oligosaccharides. International Conference on Magnetic Resonance in Biological Systems, Keystone, CO, Aug. 18-23,1996.

26. Bornmann WG. Asymmetric Total Synthesis of (+) Tacamine. 20th IUPAC Symposium on the Chemistry of Natural Products, Chicago, IL, Sept. 15-20,1996.

27. Byrd CA, Bornmann WG, Nathan CF, Ding A. The Identification of Taxol Binding Proteins Using Affinity Chromatography Seventeenth Annual Vincent duVigneaud Memorial Research Symposium. Cornell University Graduate Sschool of Medical Sciences, New York, NY, May 6, 1997.

28 28. Planchon SM, Wuerzberger SM, Pink JJ, Bornmann WG, Boothman DA. Poster #104, Structure/Function of -lapachone derivatives on apoptotic induction in HL-60 cells. 88th Annual Meeting of the American Association of Cancer Research, San Diego, CA, Apr. 12-16, 1997.

29. Pink JJ, Planchon SM, Bornmann WG, Boothman DA. Poster #117, Topoisomerase I- mediated apoptosis in human MCF-7 breast cancer cells. 88th annual meeting of the American Association of Cancer Research, San Diego, CA, Apr. 12-16, 1997.

30. Bornmann WG, Fan J, Tong WP, Lin S, Deckert P M, Bertino JR. Synthesis and biologivcal evaluation of a phenylalanine derivative of 1843U89 as a potential prodrug. 88th Annual Meeting of the American Association of Cancer Research, San Diego, CA, Apr. 12-16, 1997.

31. Chou T-C, Zheng Y-H, Zatorski A, Bornmann WG, Danishefsky SJ. Poster #117, Collateral sensitivity and the reversal of anticancer multidrug resistance (MDR) by reverse prenyl compounds. 88th Annual Meeting of the American Association of Cancer Research, San Diego, CA, Apr. 12-16, 1997.

32. Deckert PM, Fan J, Bornmann WG, Clark M, Williams C, Chou TC, Old LJ, Welt W, Huennekens FM, Bertino JR. Poster #117, Activation of Methotrexate-Phenylalanine by a Conjugate of Carbosypeptidase-A and Humanized Antibody A33. American Society of Clinical Oncology, Los Angeles, CA, May 16-19, 1998.

33. Byrd CA, Bornmann WG, Nathan CF, Ding A, Tempst P, Erdjument-Bromage H. Purification of Taxol Binding Proteins Eighteenth Annual Vincent duVigneaud Memorial Research Symposium, Cornell University Graduate School of Medical Sciences, New York, NY, May 5, 1998.

34. Bornmann WG, Hintermann S, Danishefsky SJ, Wu R, Silks LA, Live D. Total Synthesis of C-13 Labeled Neoglycoconjugate of Lewis Y Carbohydrate Epitope. 9th International Carbohydrate Symposium, San Diego, CA, Aug. 9-14, 1998.

35. Spassova M, Kothari P J, Bornmann WG, Finn RD. Syntheses of Analogs of Fluorofructose. 218th American Chemical Society National Meeting, New Orleans, LA, Aug. 22-26, 1999.

36. Sirotnak F M, Bornmann WG, Miller VA.,Scher HI, Kris MG. Co-Admistration of probenceid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Molecular Targets and Cancer Therapeutics: Discovery, Development and Clinical Validation, AACR-NCI-EORTC, Washington, DC, Nov. 16-19,1999.

37. Tian HSM, Bornmann W, Daud A, Rosales N, Yan X, Spriggs D. Effects of analogs of thalidomide on EF1alpha mediated post-transcriptional regulation in human epithelial carcinoma cells by the 3’-untranslated region of tumor necrosis factor-alpha mRNA. 91st Annual Meeting of the American Association of Cancer Research, San Francisco, CA, Apr. 12-16, 2000.

29 38. Schindler T, Bornmann W, Pellicena P. Structural Mechanism for STI-571 Inhibition of Abelson tyrosine kinase NCI-EORTC-AACR Symposium on new drugs in Cancer Therapy, , Amsterdam, The Netherlands, Nov. 7-10, 2000.

39. Sabbatini P, Kudryashov V, Danishefsky S, Livingston PO, Ragupathi G, Bornmann WG, Spassova M., Zatorski A, Spriggs D, Aghajanian C, Soignet S, Peyton M., O’Flaherty C, Curtin J, Lloyd KO. Immunization of Ovarian Cancer Patients with a Synthetic Lewis y-protein Conjugate Vaccine: Clinical and Serological Results, NCI- EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, Nov. 7-10, 2000.

40. Tian HSM, Bornmann W, Daud A, Spriggs D. Effects of the 3’-untranslated region of human tumor necrosis factor-alpha and the analogs of thalidomide on the expression of lLuciferase Reporter Gene in Human Epithelial Carcinoma Cell by 92nd Annual Meeting of the American Association of Cancer Research, New Orleans, CA, Mar. 24-28, 2001.

41. Vidal S, Sirotnak F, Scheinberg DA, Scher HI, Bornmann WG. Asymmetric Synthesis and Anti-tumor Properties of (S,S,R)-(-)- of Actinonin. 221st American Chemical Society National Meeting, San Diego, CA, Apr. 1-5, 2001.

42. Rubio MB, Bornmann WG. Synthesis of analogs of the anitmitotic agent Rhazinilam. 222nd American Chemical Society National Meeting, San Diego, CA, Apr. 1-5, 2001.

43. Bornmann WG. Structural Characterization of Potent Inhibitors of BCR-ABL Tyrosine Kinase, 2nd International Conference on Inhibitors of Protein Kinases, Warsaw, Poland, Sept. 9-19,2001.

44. Swendeman S, Nagar B, Wisniewski D, Strife A, Lambek C, Liu C, Veach D, Bornmann W, Kuriyan J, Clarkson B. Crystal structures of the c-Abl tyrosine kinase domain in complex with STI-571 and a novel Bcr-Abl inhibitor, PD173955. NCI-EORTC-AACR Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, Miami, FL, Oct. 29-Nov. 1, 2001.

45. Bornmann WG. Work in Progress Towards Developing New Anti-Cancer Agents at Memorial Sloan-Kettering Cancer Center, Department of Chemistry, Columbia Univeristy, New York, NY, Oct. 18, 2001.

46. Bornmann WG. Structural Characterization of Potent Inhibitors of BCR-ABL Tyrosine Kinase, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Jan. 23, 2002

47. Bornmann WG. Structural Characterization of Potent Inhibitors of BCR-ABL Tyrosine Kinase. New York University, New York, NY, Feb. 15, 2002.

48. Borella C, Vidal E, Lee M, Sirotnak F, Scheinberg DA, Scher HI, Bornmann WG. Poster #1032 - Asymmetric solid phase and solution parallel synthesis and anti-tumor properties of actinonin analogs. 93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA, Apr. 6-10, 2002.

30 49. Glekas A, Bornmann WG, Scher HI, Livingston P. Poster #1036 - Synthetic studies toward Sialyl lewis a . 93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA, Apr. 6-10, 2002.

50. Capiaux GM, Budak-Alpdogan T, Banerjee D, Bornmann WG, Bertino JR. Poster #1288 - Protection of murine bone marrow from pemetrexed toxicity with co-expression of mutant dihydrofolate and thymidylate synthase . 93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA, Apr. 6-10, 2002.

51. Ragupathi G, Koide F, Kagan E, Bornmann W, Spassova M, Danishefsky S, Livingston P. Poster #2784 - A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers 93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA, Apr. 6-10, 2002.

52. Ragupathi R, Slovin SF, BhutaS, Hood C, Spassova M, Bornmann WG, Scher HI, Danishefsky SJ, Livingston P. Poster #2782 - Comparison of the immune response after immunization with monovalent and hexavalent-KLH conjugate vaccines against prostate cancer. 93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA, Apr. 6-10, 2002.

53. Bornmann WG, Rubio MB, He L, Horwitz SB. Poster #3647 - Synthesis of analogs of the antimitotic agent rhazinilam. 93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA, Apr. 6-10, 2002.

54. Veach DR, Swendeman S, Nagar N, Wisniewski D, Strife A, Lambek CL, Liu C, Lee W, Bornmann WG, Kuriyan J, Bertino J, Clarkson B. Poster #4199 - Towards picomolar inhibition of Bcr-Abl: Synthesis and evaluation of a focused library of pyrido-[2,3-d]- pyrimidine tyrosine kinase inhibitors guided by X-ray crystallography and molecular modeling. 93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA, Apr. 6-10, 2002.

55. Larson SM, Gunther I, Morris M, Beattie B, Akhurst TA, Finn R, Pentlow K, Zanzonico P, Erdi Y, Humm J, Bornmann W, Smith-Jones P, Welch M, Scher H. Tumor localization of [18F]-Fluoro-Dihydro-testosterone (FDHT) versus [18F]-2-Fluoro-D- glucose (FDG) in patients with progressive, metastatic prostate cancer. Abstract #424 The Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, Jun. 2003.

56. Veach D, Doubrovin M, Beresten T, Balatoni J, Ageyeva L, Larson S, Bornmann W, Tjuvajev JG. Imaging Bcr-Abl kinase activity with novel kinase-specific irreversible ligand. Abstract #1068 The Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, Jun. 2003.

57. Glekas A, Doubrovin M, Ageyeva L, Balatoni J, Larson SM, Bornmann W, Gelovani J. Imaging EGFR expression with novel kinase-specific irreversible radioligands. Abstract #1073 The Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, Jun. 2003.

58. Glekas A, Beresten T, Doubrovin M, Ponomarev V, Tong,WP, Bornmannn WG, Gelovani J. Poster #MED-255 Synthesis and evaluation of PRIMA-1 and its analogs as 31 compounds capable of restoring normal activity to mutant p-53, The 226th American Chemical Society National Meeting, New York, NY Sept. 7-11, 2003.

60. Glekas A, Beresten T, Doubrovin M, Ponomarev V, Tong WP, Bornmannn WG, Gelovani, J. Synthesis and evaluation of PRIMA 1 and its radiolabeled analogs as probes for molecular imaging of mutant p53 expression. Poster # 3492 94th Annual Meeting of the American Association for Cancer Research National Meeting, Washington, D.C., Jul. 2003.

61. Borella CP, Lee M, Ju H, She Y, Sirotnak F, Scheinberg DA, Tong WP, Bornmann WG, Design, Synthesis and SAR of 2nd generation actinonin analogs. Poster # 3474 94th Annual Meeting of the American Association for Cancer Research National Meeting, Washington, D.C., Jul. 2003.

62. Zhang X, Glekas A, WP, Bornmannn WG, Livingston P. 2nd Generation novel synthesis of Analog of Siayl Lewis a (Lea). Poster # 465 94th Annual Meeting of the American Association for Cancer Research National Meeting, Washington, D.C., Jul. 2003.

63. Zhang X, Ye Y, Bornmannn WG, Yeueming L. Synthesis of analogs of gamma-secretase inhibitor Poster # 3469 94th Annual Meeting of the American Association for Cancer Research National Meeting, Washington, D.C., Jul. 2003.

64. Yang G, Hamel E, Bornmannn WG, Biomimetic alkaloid synthesis and SAR study of racemic Rhazinilam analogues. Poster # 454 94th Annual Meeting of the American Association for Cancer Research National Meeting, Washington, D.C., Jul. 2003.

65. Deng X, Bornmann WG, Fuks Z, Kolesnick RN, Caenorhabditis elegans ABL suppresses p53-mediated germline apoptosis after ionizing radiation Poster # 465 94th Annual Meeting of the American Association for Cancer Research National Meeting, Washington, D.C., Jul. 2003.

66. Borella CP, Bornmann WG, Scheinberg DA, Sirotnak F, Lee M. Design, synthesis and SAR of actinonin analogs. Abstracts of Papers of the American Chemical Society 226: U47-U47 252-MEDI Part 2, Sept. 2003.

67. Glekas A, Bersten T, Doubrovin M, Ponomarev V, Tong WP, Bornmann WG, Gelovani J. Synthesis and evaluation of PRIMA-1 and its analogs as compounds capable of restoring normal activity to mutant p-53. Abstracts of Papers of the American Chemical Society 226: U47-U47 255-MEDI Part 2, Sept. 2003.

68. Yang GL, Edler MC, Jung MK, Hamel E, Bornmann WG. Biomimetic synthesis and biological evaluation of racemic rhazinilam analogues. Abstracts of Papers of the American Chemical Society 226: U178-U178 393-ORGN Part 2, Sept. 2003.

69. Bornmann WG, Veach D. Conformational targeting of Abl kinase using small molecule inhibitors. Abstracts of Papers of the American Chemical Society 226: U434-U434 076- COMP Part 1 Sept. 2003.

32 70. Clarkson B, Veach D, Bornmann WG. Development of a curative treatment program for chronic myelogenous leukemia (CML). Abstracts of Papers of the American Chemical Society 226: U434-U434 077-COMP Part 1 Sept. 2003.

71. Veach DR, Lambek C, Liu CY, Duyster J, Beresten T, Li WQ, Wolff NC, Ilaria RL, Gelovani J, Miller WT, von Bubnoff N, Bornmann WG, Clarkson BD. Synthesis, in vitro, and in vivo characterization of pyrido[2,3-D]pyrimidine tyrosine kinase inhibitors. Abstracts of Papers of the American Chemical Society 226: U12-U12 67-MEDI Part 2 Sept. 2003.

72. Clarkson B, Veach D, Bornmann WG. Abs # COMP-077 Developmentof a curative treatment program for chronic myelogenous leukemia (CML). The 226th American Chemical Society National Meeting, New York, NY, Sept. 7-11, 2003.

73. Bornmann WG, Veach D. Abs # COMP-076 Conformational targeting of Abl kinase using small molecule inhibitors. The 226th American Chemical Society National Meeting, New York, NY, Sept. 7-11, 2003.

74. Veach DR, Lambek C, Liu C-Y, Duyster J, Beresten T, Li W, Wolff NC, Ilaria RL, Gelovani J, Miller WT, von Bubnoff N, Bornmann WG, Clarkson BD. Abs # MEDI-067 Synthesis, in viro and in vivo characterization of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. The 226th American Chemical Society National Meeting, New York, NY, Sept. 7-11, 2003.

75. Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL. Abstract #96 – PD166326, a novel tyrosine kinase inhibitor, has greater anti-leukemic activity than imatinib in a murine model of chronic myelogenous leukemia. 45th Annual Meeting of the American Society of Hematology, Dec 6-10, 2003 San Diego, Ca.

76. von Bubnoff N, Veach DR, Miller WT, Li WQ, Saenger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Abstract #808 –Pyrido-pyrimidine kinase inhibitors suppress wild-type and mutant Bcr-Abl. 45th Annual Meeting of the American Society of Hematology, Dec 6-10, 2003 San Diego, Ca.

77. Yuan RR, Wong P, McDevitt MR, Antczak C, Ekaterink D, Leiner I, Guirnalda P, Borella CP, Bornmann W, O'Reilly R, Pamer EG, Scheinberg DA. Abstract #1016 – Clonal deletion of CD8(+) T cells by alpha emitting suicide peptide/MHC tetramers. 45th Annual Meeting of the American Society of Hematology, Dec 6-10, 2003 San Diego, Ca.

78. Tipping AJ, Baluch S, Mahon FX, Veach DR, Bornmann WG, Clarkson BD, Goldman JM, Melo JV. Abstract #3191 – Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. 45th Annual Meeting of the American Society of Hematology, Dec 6-10, 2003 San Diego, Ca..

79. Edler MC, Yang G, Bornmann WG, Hamel E. Poster #5414-In vitro conditions promoting the formation of both microtubules and spirals by the natural prodct (-)- rhazinilam. 95th Annual Meeting of the American Association of Cancer Research, Orlando, FL, Mar. 27-31, 2004.

33 80. Ragupathi R, Koide F, Spassova M, Bornmann WG, Scher HI, Danishefsky SJ, Livingston PO. Poster #5477-Searching for a better synthetic Lewis y (Ley) analogue to immunize patient with Ley positive cancers. 95th Annual Meeting of the American Association of Cancer Research, Orlando, FL, Mar. 27-31, 2004.

81. Bommarius B, Bornmann, W. and Kalman, D. Oral Presentation. Tyrosine kinases in Poxvirus Pathogenesis. September 1-4, 2004 , International Pox and Iridovirus Conference, Oxford UK.

82. Reeves, P., McNulty, S., Bommarius B, Bornmann, W. and Kalman, D. Oral Presentation. Tyrosine kinases in Microbial Pathogenesis. October 1-4, 2004 , Southeast Regional Centers for Excellence in Bioterrorism, Birmingham Alabama

83. Spassova M, Bornmann WG, Ragupathi G, Sukenick G, Livingston P, Danishefsky S. Thesis of selected library of LEY and KH- analogs. Abstracts of Papers of the American Chemical Society 227: U271-U272-057-CARB Part 1 Mar. 28, 2004.

84. Spassova M, Bornmann WG, Ragupathi R, Sukenick G, Danishefsky SJ, Livingston PO. Abs #CARB-057-Thesis of selected library of LEY and KH analogs The 227th American Chemical Society National Meeting, Anaheim, CA, Mar. 28-Apr. 1, 2004.

85. von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Saenger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screening method for resistance of Bcr-Abl positive leukemia identifies the mutation pattern for an alternative abl kinase inhibitor. Blood 104 (11): 161A 558 Part 1 Nov. 16, 2004.

86. Maxwell DS, Bornmann WG, Lee MD, Borella CP, Scheinberg DA. Modeling Study of Several Active Actinonin Analogs in Human Peptide Deformylase Poster #13.Jorgensen Symposium; Department of Chemistry, Yale University April 29-30, 2005

87. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K, Bornmann W, Huang P, Boise LH, Abbruzzese JL, McConkey DJ. Abstract #25 ER stress: A novel therapeutic target in pancreatic cancer. NCI-EORTC-AACR Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, Philadelphia, PA, Nov 14-18, 2005.

88. Sankaranarayanapillai M, Tong WP, Pal A, Bornmann WG, Gelovani JG, Ronen SM. Abstract #B252-Magnetic resonance spectroscopy in the detection of histone deacetylase inhibition. NCI-EORTC-AACR Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, Philadelphia, PA, Nov 14-18, 2005.

89. Samudio I, Ruvolo P, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann WG, Ying YM, Evans R, Younes A, Andreeff M. Abstract # Methyl-2-cyano-3,12 dioxooleana-1,9 diene-28-oate (CDDO-Me) directly permeabilizes the inner mitochondrial membrane to inhibit electron transport and induce apoptosis: A paradigm for the facilitation of death receptor signaling. NCI-EORTC-AACR Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, Philadelphia, PA, Nov 14-18, 2005. Clinical Cancer Research 11 (24): 9152S-9152S Part 2 Suppl. S Dec. 15, 2005.

34 90. Bornmann WG “Exploring the New Frontiers in Cancer Diagnosis and Treatment with Targeted Therapeutic Molecular Imaging Agent” The 24th Annual Esther and Bingham J. Humphrey Symposium, September 23-24, 2005 Department of Chemistry, University of Vermont

91. Bommarius, B, Bornmann, W and Kalman D. Poster # 33 - SH3 domains mediate functional localization of Tec and Abl family kinases within actin pedestals formed by enteropathogenic E.coli. Annual Meeting of the British Society of Cell Biology: Signalling and Cytoskeletal Dynamics during Infection, October 2-5, 2005, Heriott-Watt University, Edinburgh, Scotland.

92. Doubrovin M, Beresten V, Veach D, Namavari M, Balatoni J, Bornmann W, Guelovani J, Larson S. Detection of bcr-abl expression in human cml model using radiolabeled analogue of abl-protein kinase inhibitor and positron-emission tomography (PET). Biology Of Blood and Marrow Transplantation 12 (2): 17-17 41 Suppl. Feb. 1, 2006

93. Bornmann, W. The Role of Theranostics in Molecular Imaging GRC: Metals in Biology, Jan 29-Feb 3, 2006, Four Points Sheraton: Harbortown, Ventura, CA.

94. Reeves, P., McNulty, S., Bornmann, W and Kalman, D. Oral Presentation. Tyrosine kinases in Poxvirus Pathogenesis.May 19-20, 2005 NIH Pox and Iridovirus Meeting, Bethesda MD

95. Reeves, P., McNulty, S., Bornmann, W and Kalman, D. Oral Presentation. Tyrosine kinases in Poxvirus Pathogenesis. October, 7, 2005 Southeast Regional Centers for Excellence in Bioterrorism, Chapel Hill NC.

96. Maxwell D, Pal A, Peng Z, Estrov V, Bornmann WG. Poster #284 – Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia. 14th Annual Spore Investigator’s Workshop, Baltimore, MD, Jul. 16-19, 2006.

97. Maxwell D, Alauddin M, Mukhopadhyay U, Ghosh P, Bornmann WG, Gelovani J. Poster #621 – In Silico Design of Thymidine Kinase Type One Substrates for PET Imaging of Proliferative Activity. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

98. Gelovani J, Ghosh P, Peng Z, Alauddin M, Bornmann WG. Poster #626 – Radiosynthesis of an ST1571 Analogue (18F-Fluro-ST1571) as a Potential PET Imaging Agent for Bcr-Abl, C-Kit, and PDGFR Expression at a Kinase Level. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

99. Gelovani J, Ying Y, Mukhopadhyay U, Tae Lim S, Shavrin A, Maxwell D, Alauddin M, Bornmann WG. Poster #627 – Radiosynthesis of 18F-fluoro-BMS-354825 for PET Imaging of SRC Expression in Tumors. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

100. Gelovani J, Ghosh P, Ying Y,Guo L, Alauddin M, Bornmann WG. Poster #646 – An Imporved Synthesis of B-D-Galactopyranosyl-(1,4’)-2’-Deoxy-2’-[18F]-Flouro-B-D- Glucopyranozide for PET Imaging of Lactose-Binding Protein Expression in Pancreatic 35 Carcinomas. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

101. Gelovani J, Guo L, Han D, Yang D, Bornmann WG. Poster #649 – A Novel Synthesis 17β-Hydroxy-16β[124]lodowortmannin for Molecular Imaging of P13K Expression with PET. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31- Sept. 2, 2006.

102. Gelovani J, Han D, Guo L, Maxwell D, Samudio I, Andreeff M, Yang D, Bornmann WG. Poster #650 – Synthesis of [124}I-ABT-737, a New Radiotracer for PET Imaging of Bcl- 2 Expression in Tumors. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

103. Gelovani J, Pal A, Peng Z, Alauddin M, Bornmann WG. Poster #651 – Development of a Novel Precursor for a Single Step Radiofluorination of FMAU in the 2 –Position. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

104. Gelovani J, Pal A, Peng Z, Alauddin M, Yang D, Bornmann WG. Poster #652 – Synthesis and Radiolabeling of SAHA Analog for Radionuclide Imaging of HDAC Expression-Occupancy in Tumors during Molecular-Targeted Therapy of Cancer. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

105. Gelovani J, Tae Lim S, Peng Z, Ghosh P, Soghomonyan S, Volgin A, Shavrin A, Alauddin M, Bornmann WG. Poster #653 – Evaluation of [18F]-ST1571 PET for Imaging Bcr-Abl and c-Kit Expression-occupancy in Tumors. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

106. Volgin A, LeRoux L, Peng Z, Ying Y, Bornmann WG, Schellingerhout D, Gelovani J. Poster #683 – Development and Validation of a Novel Technology for Production of Multi-Cellular Tumor Spheroids for High Content Screening Applications. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

107. Gelovani J, Nishii R, Pal A, Soghomonyan S, Balatoni J, Mushkudiani I, Hsien Yeh H. Mukhopadhysy U, Volgin A, Shavrin A, Maxwell D, Tong W, Alauddin M, Bornmann WG. Poster #725 – Molecular Imaging of Different EGFR Kinase Mutant NSCL Carcinomas with [124]-Mipqa PET for Prediction of Responsiveness to EGFR Kinase Inhibitors. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

108. Gelovani J, Volgin A, Ying Y, Peng Z, Schellingerhout D, Bornmann WG, Powis G. Poster #824 – Molecular Imaging of Tumor Spheroids for Screening of Nowel Inhibitors of HIF1alpha Signaling. The 5th Annual Meeting of The Society for Molecular Imaging, Hawaii, Aug. 31-Sept. 2, 2006.

109. Bornmann WG. Approaches to Theragnostic Imaging. Minisymposium on Molecular Imaging in Drug Design, 62nd Southwest Regional ACS Meeting Houston, TX, Oct. 19- 22, 2006.

36 110. Faderl S, Bornmann WG, Maxwell D, Pal A, Peng Z, Shavrin A, Harris D, Yan Q, Zhiming L, Verstovsek S, Manshouri T, Ferrajoli A, Kantarjian H, Estrov Z. APCK110, a Novel and Ptent Inhibitor of c-Kit, Blocks Phosphorylation of AKT and STAT3, Induces Apoptosis, and Inhibits Proliferations of Acute Myeloid Leukemia (AML) Cells. 48th Annual Meeting of the American Society of Hematology, Dec 9-12, 2006 Orlando, FL.

111. Maxwell D, Pal A, Peng Z, Shavrin A, Faderl S, Harris D, Van Q, Liu Z, Verstovsek S, Manshouri T, Ferrajoli A, Kantarjian H, Estrov Z, Bornmann WG. Abstract #1906 – Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia. 48th Annual Meeting of the American Society of Hematology, Dec 9- 12, 2006 Orlando, FL.

112. Kapuria V, Bartholomeusz G, Bornmann WG, Kong L, Talpaz M, Donato N. Abstract #3423 – Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism. 48th Annual Meeting of the American Society of Hematology, Dec 9-12, 2006 Orlando, FL.

113. Bommarius B, Maxwell, D, Bornmann, W and Kalman, D. Poster #A3 - Enteropathogenic E.coli is a SH3/SH2 ligand that recruits and activates tyrosine kinases required for pedestal formation. Gordon Research Conference on Phosphorylation and G Protein Mediated Signaling Networks, June 11-16, 2006, University of New England, Biddeford, ME.

114. Bommarius B, Reeves, P., McNulty, S., Bornmann, W. and Kalman, D. Oral Presentation. Tyrosine kinases in Microbial Pathogenesis. Gordon Research Conference on Phosphorylation and G Protein Mediated Signaling Networks, July, 2006, Tilton School, New Hampshire.

115. Bornmann WG. “Medicinal Chemistry for Development of Therapeutics & Imaging”. Department of Pathology, Emory University School of Medicine, November 13, 2006.

116. Pal A, Nadipuram A, Ying Y, Han D, Maxwell D, Peng Z, Bornmann W. Poster #A38- Anticancer Alkaloids: Optimized Total Synthesis of Tetrahydrosecamine. Chemistry in Cancer Research: A Vital Partnership (Joint Conference by the American Association for Cancer Research and the American Chemical Society) February 4-7, 2007, San Diego, CA.

117. Maxwell D, Bornmann W, Borella CP, Scheinberg D. Poster #B51- Modeling Study of Several Active Actinonin Analogs in Human Peptide Deformylase. Chemistry in Cancer Research: A Vital Partnership (Joint Conference by the American Association for Cancer Research and the American Chemical Society) February 4-7, 2007, San Diego, CA.

118. Pal A, Peng Z, Bornmann W. Poster #A30- New Synthesis Process of Laptinib (an EGFR and ErbB-2 Dual Tyrosine Kinase Inhibitor Under Clinical Trial). Chemistry in Cancer Research: A Vital Partnership (Joint Conference by the American Association for Cancer Research and the American Chemical Society) February 4-7, 2007, San Diego, CA.

119. Fernandez A, Peng Z, Sanguino A, Eylem O, Maxwell D, Gelovani J, Bornmann W, Lopez-Berestein G, Jianpeng M. Poster # B33-Molecularly Engineered Specificity in 37 Anti-Cancer Activity: Cell-line and Molecular Assays Translating a Structural Discriminator. Chemistry in Cancer Research: A Vital Partnership (Joint Conference by the American Association for Cancer Research and the American Chemical Society) February 4-7, 2007, San Diego, CA.

120. Ying, Yunming; Peng, Zhenghong; Pal, Ashutosh; Bornmann, William. Stereoselective synthesis C8-C25 fragment of psymberin. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), ORGN-734.

121. Pal, Ashutosh; Ying, Yunming; Peng, Zhenghong; Bornmann, William. Efficient asymmetric synthesis of the C1-C6 portion of the psymberin using Evans auxiliary controlled reaction. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), ORGN-733.

122. Pal, Ashutosh; Kurihara, Hiroaki; Peng, Zhenghong; Yang, David J.; Bornmann, William; Gelovani, Juri. Synthesis and radiolabeling of SAHA analog for radio imaging of HDAC expression-occupancy in tumors during molecular-targeted therapy of cancer. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25- 29, 2007 (2007), MEDI-163.

123. Fernandez, Ariel; Peng, Zhenghong; Bornmann, William; Gabriel, Lopez-Berestein; Maxwell, David. Molecularly engineered specificity in anticancer activity. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), MEDI-132.

124. Peng, Zhenghong; Bornmann, William; Gao, Liwei; Kim, Woo-Young; Lee, Ho-Young. The synthesis and structure-activity evaluation of deguelin analogs. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), MEDI-131.

125. Peng, Zhenghong; Bornmann, William; Pal, Ashutosh; Ghosh, Pradip; Lim, Seok Tae; Gelovani, Juri; Maxwell, David; Alauddin, Mian M. STI571 Analogs: 18F- STI571 as potential agents for PET imaging of c-kit expression at a kinase level. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), MEDI-109.

126. Ying, Yunming; Guo, Liwei; Ghosh, Pradip; Alauddin, Mian M.; Bornmann, William; Gelovani, Juri. An improved synthesis of beta-D-galactopyranosyl-(1,4')-2'-deoxy-2'- [18F]-fluoro-beta-D-glucopyranoside for PET imaging of lactose-binding protein expression. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), MEDI-108.

127. Ying, Yunming; Mukhopadhyay, Uday; Alauddin, Mian M.; Bornmann, William; Gelovani, Juri. Radiosynthesis of 18F-fluro-BMS-354825 for PET imaging of SRC expression in tumors. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), MEDI-104.

128. Maxwell, David S.; Ying, Yunming; Han, Dongmei; Peng, Zhenghong; Kantarjian, Hagop; Stellrecht, Christine; Gandhi, Varsha; Bornmann, William G.. Structure-based drug design of c-met inhibitors for use in the treatment of multiple myeloma. Abstracts 38 of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), MEDI-115.

129. Maxwell, David S.; Pal, Ashutosh; Peng, Zhenghong; Shavrin, Alexandr; Faderl, Stefan; Harris, David; Van, Quin; Liu, Zhiming; Verstovsek, Srdan; Manshouri, Taghi; Ferrajoli, Alessandra; Kantarjian, Hagop; Estrov, Zeev; Bornmann, William G.. Structure-based drug design of c-kit inhibitors for use in the treatment of acute myeloid leukemia. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25- 29, 2007 (2007), MEDI-114.

130. Han, Dongmei; Bornmann, William G.; Gutterman, Jordan U. Synthesis toward the active side chains of avicins and their analogs. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), MEDI-107.

131. Han, Dongmei; Guo, Liwei; Yang, David J.; Kurihara, Hiroaki; Yeh, Hsin Hsien; Bornmann, William G.; Gelovani, Juri G. Improved synthesis of 17 -hydroxy-16 - [124I]iodowortmannin for molecular imaging of PI-3 kinases expression with PET. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25- 29, 2007 (2007), MEDI-106.

132. Han, Dongmei; Guo, Liwei; Maxwell, David S.; Yang, David J.; Lim, Seok Tae; Samudio, Ismael; Andreeff, Michael; Bornmann, William G.; Gelovani, Juri G. Synthesis of [124I]Iodo-ABT-737, a PET imageable tracer for BCl-2 expression in tumors. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007), MEDI-105.

133. Fernandez, Ariel; Peng, Zhenghong; Bornmann, William; Maxwell, David; Lopez- Berestein, Gariel; Gelovani, Juri; Sood, Anil; Sanguino, Angela, Molecularly engineered specificity in anti-cancer activityAbstract Number: 3962. 100th Annual Meeting of the American Association for Cancer Research National Meeting, Los Angeles, CA April 14- 18, 2007.

134. Litvin-Vechnyak, Tatiana; Lavnikova, Natalia; Abali, Emine; Peng, Zhenghong; Bornmann, William; Bertino, JosephPSMA activation of antifolate prodrugs for treatment of prostate cancerAbstract Number: 5732, 100th Annual Meeting of the American Association for Cancer Research National Meeting, Los Angeles, CA April 14-18, 2007.

135. Tavana, Bahareh; Huang, Zai-Feng; Khokhar, Abdul R.; Bornmann, William G.; Siddik, Zahid H. Downregulation of p21 induces cisplatin resistance in tumor cells harboring wild-type p53 Abstract Number: 3194 100th Annual Meeting of the American Association for Cancer Research National Meeting, Los Angeles, CA April 14-18, 2007.

136. Maxwell, David S.; Pal, Ashutosh; Peng, Zhenghong; Shavrin, Alexandr; Faderl, Stefan; Harris, Davis; Van, Quin; Zhiming, Liu; Verstovsek, Srdan; Manshouri, Taghi; Ferrajoli, Alessandra; Kantarjian, Hagop; Estrov, Zeev; Ozturk, Eylem; Sanguino, Angelo; Lopez- Berestein, Gabriel; Bornmann, William G. Structure-based drug design of c-kit inhibitors for use in the treatment of several types of cancer Abstract Number: 3959, 100th Annual Meeting of the American Association for Cancer Research National Meeting, Los Angeles, CA April 14-18, 2007.

39 137. Kapuria, Vaibhav; Bartholomeusz, Geoffrey; Kong, Ling Y.; Bornmann, William G.; Donato, Nicholas J. Sub-cellular compartmentalization of Jak2 as a unique mechanism for the inhibition of Jak2-Stat3 signaling Abstract Number: 2390, 100th Annual Meeting of the American Association for Cancer Research National Meeting, Los Angeles, CA April 14-18, 2007.

138. Faderl, S., Bornmann, W., Maxwell, D., Peng, Z., Van, Q., Liu, Z., Verstovsek, S., Ferrajoli, A., Kantarjian, H.M., Estrov, Z. Molecular targeting in acute myeloid leukemia (AML): APcK110 is a new inhibitor of c-Kit in AML blasts. Abstract Number 7019. 43rd Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, Ill June 1-5, 2007 J. Clin. Oncol. 25: 361s, 2007.

139. Molecular-Genetic Image-Guided Sequencing of Radiotherapy with Targeted HIF-1 Inhibition. Schwartz, David L.; Oh, Junghwan; Williams, Ryan; He, Yi; Lemos, Robert; Alauddin, Mian; Kuno, Norihito; Bornmann, Willliam; Powis, Garth; Gelovani, Juri; Abstract Number 0060. Joint Molecular Imaging Conference (AMI & SMI) Providence Rhode Island Sept 8-11, 2007

140. Sankaranarayanapillai, Madhuri; In vivo detection of Histone deacetylase inhibition by Magnetic Resonance Spectroscopy Abstract Number 0343. Joint Molecular Imaging Conference (AMI & SMI) Providence Rhode Island Sept 8-11, 2007

141. Volgin, Andrei; Bornmann, William; Molecular imaging ans selection of the novel LG-2 inhibitors of HIF-1 alpha signaling. Abstract Number 0551. Joint Molecular Imaging Conference (AMI & SMI) Providence Rhode Island Sept 8-11, 2007

142. Najjar, Amer; Bornmann, William; Differential Positron Emission Tomography Imaging Using a Herpes Simplex Virus-1 Thymidine Kinase Variant with Enhanced Acycloguanoside Substrate Specificity. Abstract Nuber 1044. Joint Molecular Imaging Conference (AMI & SMI) Providence Rhode Island Sept 8-11, 2007

143. Bornmann, William; Ligand and structure based screening. A Worshop on High Throughput/High Content Screening and its application to Target-based Drug Discovery Research. John S. Dunn GCC Consortium for Chemical Genomics Houston, Texas November 8, 2007

144. Vaibhav Kapuria, Geoffrey Bartholomeusz, Ling-Yuan Kong, William Bornmann, Zhenghong Peng, Ashutosh Pal, David Maxwell, Moshe Talpaz, Nicholas Donato; [ A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling. Abstract Number 1556. 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, GA December 8-11, 2007

145. Nicholas Donato, Vaibhav Kapuria, Hanshi Sun, David Maxwell, Geoffrey Bartholomeusz, William Bornmann, Zhenghong Peng, Ashutosh Pal, Moshe Talpaz; [ Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation. Abstract Number 1003. 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, GA December 8-11, 2007

146. Pal, Ashutosh; Maxwell, David; Peng, Zhenghong; Sung, Bokyung; Pham, Lan V.; Tamayo, Archie; Ford, Richard; Aggarwal, Bharat B.; Bornmann, William. Design and 40 synthesis of potent curcumin analogs using microwave chemistry as anticancer agents. 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008 (2008), MEDI-284.

147. Peng, Zhenghong; Pal, Ashutosh; Maxwell, David S.; Bornmann, William; Wang, Shimei; Donato, Nicholas; Talpaz, Moshe. Signaling protein modulators as therapeutic agents based on tyrphostin dimer like structure. 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008 (2008), MEDI-095.

148. Nishii, Ryuichi; Williams, Ryan; Volgin, Andrei; Powis, Garth; Schwartz, David; Peng, Zheng-Hong; Lemos, Robert; Kuno, Norihito; Soghomonyan, Suren; J, Oh; Gelovani, Juri; Bornmann, William; Aluaddin, Mian; Mukhopadhay, Uday; Molecular-genetic image guided studies of the antitumor HIF-1α inhibitor PX-478 in combination with radiation. Abstract Number: 2566, 101st Annual Meeting of the American Association for Cancer Research National Meeting, April 12-16, 2008, San Diego CA

149. Leslie, Kenneth; Veach, Darren; Travis, William D.; Pao, William; Mark, Kevin G.; Gerald, William L.; Gao, Sizhi Paul; Clarkson, Bayard; Bromberg, Jacqueline F.; Bornmann, William; Motoi, Noriko; Mutations in the EGFR kinase domain mediate Stat3 activation via IL-6 production in human lung adenocarcinomas. Abstract Number: 3544, 101st Annual Meeting of the American Association for Cancer Research National Meeting, April 12-16, 2008, San Diego CA

150. Konopleva, Marina; Samudio, Ismael; Andreeff, Michael; Bornmann, William; Zeng, Zhihong; Simultaneous blockade of the Bcl-2 and mTOR/Akt pathways induces apoptosis in AML cells under bone marrow microenvironment simulating conditions. Abstract Number: 3719, 101st Annual Meeting of the American Association for Cancer Research National Meeting, April 12-16, 2008, San Diego CA

151. Bornmann, William G.; Esteva, Francisco J.; Hortobagyi, Gabriel N.; Pal, Ashutosh; Ueno, Naoto T.; Zhang, Dongwei; Lapatinib activity is independent of EGFR expression levels in HER2-overexpressing breast cancer cells. Abstract Number: 4855, 101st Annual Meeting of the American Association for Cancer Research National Meeting, April 12- 16, 2008, San Diego CA

152. Bornmann, William G.; “Why is there a need for Chemistry at Cancer Centers?” Department of Chemistry, Rice University April 16, 2009

153. Quansheng Zhu, Changye Zou, Kerry D Smith, Ie McCutcheon, Jm Slopis, F Meric- Bernstam, Wg Bornmann, G Mills, AJ Lazar, Re Pollock, Dina Lev. #2819 Dual targeting of AKT and mTOR: A potential therapeutic approach for the malignant peripheral nerve sheath tumors. Abstract #2819 100th Annual Meeting of the American Association for Cancer Research National Meeting, April 18-22, 2009, Denver, Colorado

154. Fredika M. Robertson, Carolyn S. Hall, William Bornmann, Ashatosh Pal, Zhenhong Peng, Wendy Woodward, Massimo Cristofanilli. Targeting histone deacetylase to inhibit the stem cell phenotype of inflammatory breast cancer cells. Abstract #2841 100th Annual Meeting of the American Association for Cancer Research National Meeting, April 18- 22, 2009, Denver, Colorado

41 155. Twee Tsao, Marina Konopleva, Xiaoyang Ling, Kensuke Kojima, Julie C. Watt, Duncan H. Mak, Monique Verhaegen, William G. Bornmann, Maria Soengas, Michael Andreeff. Non-genotoxic p53 activation and blockade of Bcl-2 signaling synergistically induce apoptosis in AML through induction of Noxa and Bak/Bax heterodimerization. Abstract #2047 100th Annual Meeting of the American Association for Cancer Research National Meeting, April 18-22, 2009, Denver, Colorado

156. Nicholas J. Donato, Hanshi Sun, Vaibhav Kapuria, Luke Peterson, Zhenghong Peng, David Maxwell, William Bornmann, Moshe Talpaz. Inhibition of BCR-ABL signaling in imatinib sensitive and resistant chronic myelogenous leukemia and progenitor cells through small molecule-mediated BCR-ABL ubiquitination and aggresomal deposition. Abstract #3720 100th Annual Meeting of the American Association for Cancer Research National Meeting, April 18-22, 2009, Denver, Colorado

157. Vaibhav Kapuria, Luke Peterson, Hanshi Sun, Geoffrey Bartholomeusz, William Bornmann, Moshe Talpaz, Nicholas J. Donato. Activation of a novel Jak-Stat inhibitory pathway by a small molecule. Abstract #4773 100th Annual Meeting of the American Association for Cancer Research National Meeting, April 18-22, 2009, Denver, Colorado

158. Andreeff M., Fiegl M., Konopleva M., Korchin B., Kaluarachchi K., Bornmann W.G., Guthrie, P.H., Harmancey R., Taegtmeyer H., and Samudio I.J. and Poster Presentation #3779harmacological Inhibition of Fatty Acid Oxidation as a Novel Therapeutic Concept for Acute Myeloid Leukemia. 51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, December 5-8, 2009

159. Faderl S., Bueso-Ramos C., Liu Z., Pal A., Bornmann W., Harris D., Hazan-Halevy I., Kantarjian H.M., and Estrov Z.; Oral and Poster Presentation #1045 APcK 110, a novel Inhibitor of Kit, Extends Survival of NOD-SCID Mice in An AML Xenograft Model. 51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, December 5-8, 2009

160. Donato N.J., Sun H, Kapuria V., Peterson L.F., Bartholomeusz G, Bornmann W. G., and Talpaz M.; Oral and Poster Presentation #3303 WP1130 Inhibits Signaling through BCR- ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells. M.51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, December 5-8, 2009

161. Kapuria V., Peterson L.F., Bornmann W., Talpaz M. and Donato Poster and Oral Presentaion #2907 Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130. 51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, December 5-8, 2009

162. Xie X, Bartholomeusz C, Maxwell DS, Peng Z, A Kazansky, Bornmann WG, and NT. Ueno UT, Poster P6-15-20 Development of PEA-15-Based Therapy in Breast Cancer in a Preclinical Study Thirty-Third Annual CTRC-AACR San Antonio Breast Cancer Symposium-- Dec 8-12, 2010; San Antonio, TX

163. Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD,Fang B, Jack A. Roth JA, Poster # LB-400 STAT3 mediates resistance to MEK inhibitor through 42 microRNA miR-17 102nd Annual National Meeting of the American Association for Cancer Research, Apr 2-6, 2011; Orlando, FL

164. Bornmann, WG.; Ford, R J.; Lan, PV.; Li, C; Maxwell, D; Pal, A; Peng, Z; Sun, D; Tamayo, A T. Poster # A129 Development of Turmerax Therapeutic Compounds in Aggressive, Refractory B Cell Non-Hodgkin’s Lymphoma. 2011 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, November 12-16, 2011, San Francisco, CA

165. Bornmann, WG.; Kupferman, ME.; Lee, J; Maxwell, D; Peng, Z; Sun, D Poster # A122 Therapeutic Modulation of Trkb in Head and Neck Squamous Cell Carcinoma 2011 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, November 12-16, 2011, San Francisco, CA

166. Nawrocki ST, Espitia CM, Kelly KR, Bornmann WG, Carew JS;Oral and Poster Presentation #84 mall Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Acute Myeloid leukemia. 53rd Annual Meeting of American Society of Hematology Annual, San Diego, CA, December 10-13, 2011

167. Nawrocki ST, Kelly KR, Espitia CM,Bachier C, Bornmann WG, Carew JS Poster # 529 Targeting SIRT1 Activity: a Novel Strategy for Acute Myeloid Leukemia Therapy, 2012 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, November 6-9, 2012, Dublin, Ireland

168. Maxwell DS, Sun D, Peng Z, Martin DV, Bornmann WG.Poster #W-29 Synthesis of a Macrocycle Based on Linked Amino Acid Mimetics (LAAM), 43rd National Organic Chemistry Symposium, June 23-27, 2013, Seattle, WA

169. Peng Zhenghong, Maxwell David S, Sun Duoli, Darnay Bryant G, Bornmann William G. Structure-based drug design of TRAF6 inhibitors 246th ACS National Meeting, Indianapolis, IN, September 8-12, 2013, MEDI-259.

170. Maxwell David S, Peng Zhenghong, Sun Duoli, Yung W.K. Alfred, Lu Zhimin, Bornmann William G. Structure-based drug design of pyruvate kinase inhibitors 246th ACS National Meeting, Indianapolis, IN, September 8-12, 2013, MEDI-313.

171. Sun Duoli, Maxwell David S, Peng Zhenghong, Ahmed Ahmed A, Redondo Clara, Bast Robert C, Bornmann William G. Structure-based drug design and synthesis of salt- inducible kinase 2 (SIK 2) inhibitors 246th ACS National Meeting, Indianapolis, IN, September 8-12, 2013, MEDI-315.

172. Maxwell David Sun Duoli, Peng Zhenghong, Qi Wei, McConkey Peng Zhenghong,, Abbruzzese James L., Bornmann William G. Poster # B101 Design and optimization of a new series of HSP70 inhibitors for use in the treatment of pancreatic cancer. 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, October 19-23, 2013, Boston, MA

173. Zuo M, Maxwell D, Bhanu Prasad BA, Peng Z, Bornmann W, Javle MM. Development of targeted inhibitors against RecQ1 helicase Poster # 5361, 102nd Annual National Meeting of the American Association for Cancer Research, Apr 5-9, 2014; San Diego, CA 43

174. Bornmann W, Peng Z, Maxwell D, Sun D, Bhanu Prasad BA, Talpaz M, Donato N, Levitzki A. Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I), Poster # 2698, 102nd Annual National Meeting of the American Association for Cancer Research, Apr 5-9, 2014; San Diego, CA 175. Chiao PJ, Zhuang Z, Xia Q, Schuber PT, Jr.1, Sun D, Peng Z, Maxwell DS, Bornmann WG. Development of novel TAK1 inhibitors for pancreatic cancer. Poster # 1727, 102nd Annual National Meeting of the American Association for Cancer Research, Apr 5-9, 2014; San Diego, CA

176. Huang X, Moore Z, Luo X, Chakrabarti G, Ilcheva M, Brekken R, Burma S, Gao J, Deberardinis R, Bornmann W, Hergenrother P, Boothman DA. DNA repair and inhibitors are tumor-selective when combined with NQO1 bioactivatable drugs for therapy against pancreatic and nonsmall cell lung cancers. Poster # 787, 102nd Annual National Meeting of the American Association for Cancer Research, Apr 5-9, 2014; San Diego, CA

177. Zuo M, Maxwell D, Bhanu Prasad BA, Peng Z, Bornmann W, Javle MM. Development of targeted inhibitors against RecQ1 helicase Poster # 19, 34th National Medicinal Chemistry Symposium, May 18-21, 2014; Charleston, SC.

178. Bornmann, W. “A Window to Discovery with Medicinal Chemistry”. Department of Molecular Biosciences, University of California – Davis, October 26, 2015

179. Lin, E., Satani, N., Hammoudi, N., Leonard, P., Marszalek, J., Sun, Y., Bornmann, W., Maxwell, D., Czako, B., DiFrancesco, M., Peng, Z., Wang, A., DePinho, A. and Muller, F. Poster #310 - Collateral Lethality: One Step Closer to the Clinic 2015 Innovations in Cancer Prevention and Research Conference NOV 2015

180. Lin, E., Maxwell, D., Leonard, P., Peng, Z., Satani, N., Sun, Y., Hammoudi, N., Czako, B., DiFrancesco, M., Bornmann, W., DePinho, R. and Muller, F. Poster #385 - SF2312, A Natural Phosphonate Inhibitor of Enolase 2015 Innovations in Cancer Prevention and Research Conference NOV 2015

181. Lin, E., Satani, N., Hammoudi, N., Leonard, P., Marszalek, J., Sun, Y., Bornmann, W., Maxwell, D., Czako, B., DiFrancesco, M., Peng, Z., Wang, A., DePinho, R. and Muller, F. Poster #C183: Pomhex: a cell-permeable high potency Enolase inhibitor with in vivo anti-neoplastic activity AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference NOV2015

182. Lin, Y-H., Satani, N., Hammoudi, N., Leonard, P., Maxwell, D., Peng, Z., Link, T., Lee, G., Bosajou, A., Sun, D., DiFrancesco, E., Czako, B., Wang, A., Bornmann, W., DePinho, R. and Muller, F. Poster # 68: SF-2312, A Natural Phosphonate Inhibitor of Enolase 14th International Conference on the Chemistry of Antibiotics and other Bioactive Compounds OCT 2015

183. Lin, Y-H., Satani, N., Hammoudi, N., Leonard, P., Marszalek, J., Sun, Y., Bornmann, W., Maxwell, D., Czako, B., DiFrancesco, M., Peng, Z., Wang, A., DePinho, R. and Muller,F. Poster#KWO16-00031 Pomhex: A High Potency Enolase Inhibitor with in- vivo Anti-neoplastic Activity 8th International Conference of Contemporary Oncology MAR 2016

44

AFFILIATIONS

1. American Chemical Society, Division of Organic Chemistry and Division of Medicinal Chemistry 2. American Society of Heamatology 3. American Society of Clinical Oncology 4. American Society of Pharmacognosy 5. American Society of Pharmaceutical Scientists 6. American Institute of Chemists 7. American Association for Cancer Research 8. International Chemical Biology Society 9. Sigma Xi, The Scientific Research Society 10. American Associates for the Advancement of Science 11. New York Academy of Sciences 12. Phytochemical Society of North America 13. Society for Medicinal Plant Research 14. International Society of Heterocyclic Chemistry 15. Phytochemical Society of Europe 16. The Royal Society of Chemistry 17. Society for Biomolecular Sciences 18. Society of Nuclear Medicine and Molecular Imaging 19. European Society for Molecular Imaging 20. World Molecular Imaging Society

PROFESSIONAL ACTIVITIES

1. Chair of the Greater Houston Section of the American Chemical Society (2014 – Present) 2. Member of the Cancer Drug Development and Therapeutics (CDDT) SBIR/STTR Study Scection (2005-Present) 3. Member of the Peer Review Committee on Cancer Drug Development – The American Cancer Society (1997-2002) 4. Co-Chair, Drug Targeting Minisymposium, Eighty-Eighth Annual Meeting of the American Association of Cancer Research (1997) 5. Technology Review Committee, The University of Texas M.D. Anderson Cancer Center (2004-2012) 6. Institutional Chemical and Biosafety Committee, The University of Texas M.D. Anderson Cancer Center (2004-2012) 7. Member of the John S. Dunn Gulf Coast Consortium for Chemical Genomics (2004 – Present)